{"meta":{"query_hash":"ed0f6a6f7fe7","filters":{"venue":"PharmacoEconomics - Open"},"cohort_total":81,"direct_labels_cover":0,"predictions_cover":81,"exported":81,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/ed0f6a6f7fe7","api":"https://metacan.xera.ac/api/v1/cohort?venue=PharmacoEconomics+-+Open"},"results":[{"id":"W2555011614","doi":"10.1007/s41669-016-0007-y","title":"Utilization, Spending, and Price Trends for Quinolones in the US Medicaid Programs: 25 Years’ Experience 1991–2015","year":2016,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Antibiotics Pharmacokinetics and Efficacy","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicaid; Reimbursement; Quarter (Canadian coin); Medical prescription; Pharmacy; Medicine; Prescription drug; Population; Family medicine; Environmental health; Pharmacology; Health care; Geography; Economic growth; Economics","score_opus":0.10637381173363936,"score_gpt":0.42563498322346993,"score_spread":0.3192611714898306,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2555011614","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894967,0.0008698278,0.00006159634,0.0017384465,0.000014370963,0.000024212513,0.005919566,0.000012190012,0.001863026],"genre_scores_gemma":[0.9901688,0.0015997605,0.0001248162,0.00055470876,0.00004598783,0.000037560952,0.006619769,0.0000071096256,0.0008414748],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992493,0.00008983045,0.0000829197,0.00008408857,0.0002704841,0.00022336474],"domain_scores_gemma":[0.99758565,0.00017863979,0.0013330257,0.0000376782,0.00038311884,0.00048181988],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010332312,0.00017952488,0.00020750784,0.0014473791,0.00059628306,0.0009023348,0.00046441663,0.0004711966,0.0014697005],"category_scores_gemma":[0.0036668063,0.00022004105,0.0005963791,0.0027488936,0.00034124448,0.0012317982,0.001084431,0.0010145947,0.00025142543],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000046474936,0.00010900045,0.9871688,0.000026510763,0.000055188244,0.00011095309,0.000601086,0.00014774494,0.00010105227,0.00014209209,0.003496639,0.0079944115],"study_design_scores_gemma":[0.0000024758501,0.000026089945,0.99756753,0.00002378622,0.000011360758,0.00008367976,0.00051874743,0.00015958055,0.000040930947,0.000017048438,0.0015445012,0.000004274749],"about_ca_topic_score_codex":0.1311992,"about_ca_topic_score_gemma":0.16018313,"teacher_disagreement_score":0.1311992,"about_ca_system_score_codex":0.0027334602,"about_ca_system_score_gemma":0.0024125413,"threshold_uncertainty_score":0.26087105},"labels":[],"label_agreement":null},{"id":"W2557026970","doi":"10.1007/s41669-016-0004-1","title":"Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review","year":2016,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"","keywords":"Proxy (statistics); Reimbursement; Listing (finance); Drug prices; Economics; Product (mathematics); Actuarial science; Econometrics; Health care; Financial economics; Public economics; Finance; Computer science; Economic growth","score_opus":0.6938985898768593,"score_gpt":0.6033221729835111,"score_spread":0.09057641689334817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2557026970","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001989242,0.9976712,0.0005565692,0.0009029432,0.00013783677,0.000038314272,0.00007176914,0.0000073414044,0.00041510994],"genre_scores_gemma":[0.0061732787,0.9910403,0.0019479633,0.00039527708,0.00020136918,0.00008289678,0.00008963613,0.0000062324025,0.00006291653],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9852309,0.0076014693,0.0028173707,0.00065838365,0.0034994031,0.00019243927],"domain_scores_gemma":[0.82809573,0.15467758,0.0090726875,0.001099493,0.006701168,0.00035335496],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.027438989,0.0017536166,0.0050490876,0.00931659,0.0003698101,0.0036390007,0.002382134,0.0028848627,0.004299976],"category_scores_gemma":[0.124948315,0.00096699194,0.00473532,0.009672943,0.00088023505,0.003843325,0.0011247762,0.0024749814,0.0006664574],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023559164,0.000083219915,0.0018793565,0.13393828,0.0028032148,0.000085322295,0.000113334936,0.0018059604,0.00006748281,0.0042223744,0.012956094,0.8418099],"study_design_scores_gemma":[0.00044517918,0.00042998514,0.012726465,0.672324,0.017778575,0.0010298922,0.000499126,0.005996268,0.00064573594,0.017535044,0.27029714,0.00029263494],"about_ca_topic_score_codex":0.004037522,"about_ca_topic_score_gemma":0.0064169597,"teacher_disagreement_score":0.972561,"about_ca_system_score_codex":0.002949626,"about_ca_system_score_gemma":0.0057965247,"threshold_uncertainty_score":0.14511293},"labels":[],"label_agreement":null},{"id":"W2581612511","doi":"10.1007/s41669-017-0011-x","title":"Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Astellas Pharma Global Development; Astellas Pharma Europe; Astellas Pharma; Canadian Urological Association; Duchesnay; Pfizer","keywords":"Mirabegron; Tolterodine; Overactive bladder; Oxybutynin; Solifenacin; Medicine; Urology; Cohort; Internal medicine","score_opus":0.15893044462834857,"score_gpt":0.5192326041491452,"score_spread":0.3603021595207966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2581612511","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9611485,0.015251272,0.004243919,0.004539654,0.0001965779,0.00028107615,0.0051280507,0.0000396507,0.009171268],"genre_scores_gemma":[0.997543,0.001030375,0.0003333242,0.00019340104,0.00001032306,0.000032388318,0.0004059115,0.0000042674915,0.0004471312],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99637055,0.002558764,0.00015340961,0.00023940922,0.0002734045,0.00040438448],"domain_scores_gemma":[0.9943124,0.0037873369,0.0010465382,0.00009844232,0.00041153026,0.00034378],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0034930662,0.00072449737,0.0010143355,0.0007898114,0.00027769903,0.0021094107,0.00077595346,0.0014796392,0.0032255473],"category_scores_gemma":[0.0145793045,0.00056473474,0.0022422737,0.0008604451,0.00060534343,0.0015104997,0.001213076,0.0011262499,0.00018333354],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008148471,0.00029975318,0.07993913,0.0018202941,0.002459303,0.0016747017,0.0002037374,0.8699391,0.0007301505,0.008522703,0.0041273083,0.022135288],"study_design_scores_gemma":[0.0034078837,0.0072414693,0.13752678,0.002359584,0.0035296043,0.0024178678,0.001313835,0.8211525,0.0014245164,0.009843788,0.009500364,0.00028189438],"about_ca_topic_score_codex":0.05862328,"about_ca_topic_score_gemma":0.028748076,"teacher_disagreement_score":0.05862328,"about_ca_system_score_codex":0.010083655,"about_ca_system_score_gemma":0.002332295,"threshold_uncertainty_score":0.116564095},"labels":[],"label_agreement":null},{"id":"W2582749134","doi":"10.1007/s41669-017-0013-8","title":"Authors’ Reply to Holko: “Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review”","year":2017,"lang":"en","type":"letter","venue":"PharmacoEconomics - Open","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"","keywords":"Economics; Financial economics; Econometrics","score_opus":0.2637735742554665,"score_gpt":0.4504590824979789,"score_spread":0.1866855082425124,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2582749134","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000086073436,0.001018902,0.000055400524,0.9845405,0.013793971,0.0000073376373,0.00007649932,0.000012682569,0.00040858667],"genre_scores_gemma":[0.00082139065,0.00058549846,0.0000805578,0.98102784,0.016474638,0.000019404471,0.000014119787,0.00001181466,0.00096484105],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99337703,0.00210036,0.0014270365,0.0008188141,0.0017370303,0.0005397425],"domain_scores_gemma":[0.9566413,0.028175,0.0033584177,0.0008930675,0.008830166,0.0021020852],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009282969,0.00079361186,0.0020010455,0.0012316046,0.0024519209,0.0037321243,0.002357991,0.049518324,0.0061359163],"category_scores_gemma":[0.07342687,0.00097383367,0.0019286401,0.0015598974,0.0028171088,0.0045147277,0.0017520139,0.04611826,0.007872386],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00005994215,0.000009923575,0.0002621756,0.0000791844,0.000016212967,0.00032192716,0.000087112814,0.00002922286,0.00006090068,0.0010992775,0.9945221,0.0034520635],"study_design_scores_gemma":[0.00021864861,0.0000783984,0.0016807761,0.0012192548,0.000081905615,0.0018075933,0.00055028254,0.00045856618,0.00048738782,0.009798539,0.9834471,0.00017148166],"about_ca_topic_score_codex":0.0061531872,"about_ca_topic_score_gemma":0.008082881,"teacher_disagreement_score":0.049518324,"about_ca_system_score_codex":0.0046371534,"about_ca_system_score_gemma":0.0066009657,"threshold_uncertainty_score":0.049093604},"labels":[],"label_agreement":null},{"id":"W2601604409","doi":"10.1007/s41669-017-0018-3","title":"Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR)","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Cancer Care Ontario; St. Michael's Hospital","funders":"","keywords":"Consistency (knowledge bases); Activity-based costing; Drug pricing; Medicine; Political science; Actuarial science; Business; Accounting; Computer science","score_opus":0.7627049803111466,"score_gpt":0.6465122802148523,"score_spread":0.11619270009629434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2601604409","genre_codex":"review","genre_gemma":"empirical","domain_codex":"methods","domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":"methods","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.04920618,0.3725695,0.16708481,0.16897112,0.033684608,0.15181172,0.022127666,0.0011659996,0.03337844],"genre_scores_gemma":[0.32349098,0.07018315,0.3312085,0.027639546,0.004765714,0.23161101,0.0057811914,0.00089264865,0.0044273064],"study_design_codex":"systematic_review","study_design_gemma":"observational","domain_scores_codex":[0.07088842,0.5881061,0.2472064,0.0118429335,0.07854749,0.0034086306],"domain_scores_gemma":[0.023774056,0.7332744,0.0922134,0.033847194,0.11532447,0.0015663994],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.78523934,0.002596354,0.007662934,0.037950035,0.007303895,0.022183638,0.009231211,0.009031983,0.00440032],"category_scores_gemma":[0.9431101,0.0048496006,0.009926333,0.052133154,0.009117897,0.009115097,0.009503063,0.006167913,0.0013407436],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00380908,0.00024906112,0.03200168,0.4992923,0.017490415,0.0014272311,0.040227644,0.0042449892,0.00226301,0.03467729,0.09477482,0.26954252],"study_design_scores_gemma":[0.0026549266,0.0011346034,0.044648234,0.5591845,0.018564388,0.0013204727,0.019228598,0.008357392,0.005203272,0.060061056,0.27836657,0.0012761385],"about_ca_topic_score_codex":0.025644919,"about_ca_topic_score_gemma":0.050304282,"teacher_disagreement_score":0.9743551,"about_ca_system_score_codex":0.040799152,"about_ca_system_score_gemma":0.11749347,"threshold_uncertainty_score":0.29601997},"labels":[],"label_agreement":null},{"id":"W2609661473","doi":"10.1007/s41669-017-0022-7","title":"Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Michael's Hospital; Toronto Public Health; Public Health Ontario; University of Toronto","funders":"Canadian Institutes of Health Research; Tufts Medical Center","keywords":"Medicine; Oncology; Internal medicine","score_opus":0.6709276885782226,"score_gpt":0.5865158343262132,"score_spread":0.08441185425200937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2609661473","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.89037836,0.0533627,0.008284687,0.030043455,0.00024234447,0.00029338282,0.0013906171,0.00004331757,0.015961152],"genre_scores_gemma":[0.99432147,0.002509099,0.0017774387,0.0009102755,0.00013584371,0.00004642692,0.00018798368,0.000012360191,0.00009908454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97412884,0.016431674,0.0029791354,0.0019882792,0.0032406594,0.0012313019],"domain_scores_gemma":[0.7793737,0.192653,0.016052509,0.0054889987,0.004813167,0.0016187675],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.034379672,0.000459175,0.0013826466,0.0044929,0.0008080697,0.00270076,0.0010668138,0.0020229253,0.0037713088],"category_scores_gemma":[0.14843662,0.00037051833,0.0033345306,0.004418504,0.001675188,0.0035566285,0.0019806025,0.0032393301,0.00024035855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029781223,0.00021131992,0.84428924,0.001829192,0.00329435,0.00977901,0.0015963386,0.004398503,0.00086810783,0.019990247,0.0060623875,0.10470315],"study_design_scores_gemma":[0.00066824997,0.0011906824,0.8252964,0.003884851,0.00789106,0.04168015,0.00875782,0.023644345,0.0018397436,0.06748883,0.017259622,0.00039819168],"about_ca_topic_score_codex":0.005181856,"about_ca_topic_score_gemma":0.0058520553,"teacher_disagreement_score":0.034379672,"about_ca_system_score_codex":0.0028735702,"about_ca_system_score_gemma":0.0012376191,"threshold_uncertainty_score":0.18181926},"labels":[],"label_agreement":null},{"id":"W2617296499","doi":"10.1007/s41669-017-0030-7","title":"Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; Programs for Assessment of Technology in Health Research Institute; Impact","funders":"","keywords":"Bevacizumab; Ovarian cancer; Medicine; Oncology; Internal medicine; Cancer; Chemotherapy","score_opus":0.10839309429298337,"score_gpt":0.43427039666966477,"score_spread":0.3258773023766814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2617296499","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.87639385,0.020684158,0.012752335,0.010627053,0.00026149116,0.004494341,0.017601281,0.00016987488,0.057015628],"genre_scores_gemma":[0.98949385,0.002369325,0.0035950271,0.00040008774,0.000019953703,0.00036970447,0.0020160438,0.00001807713,0.0017178694],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9964833,0.0017757398,0.00011757218,0.00016653516,0.0008731245,0.00058367226],"domain_scores_gemma":[0.9943112,0.002635347,0.0005242603,0.0001097712,0.0017967623,0.00062255247],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0053307815,0.00096770807,0.0010031463,0.0017884005,0.0011525869,0.0022970494,0.00173565,0.0009871442,0.0038781164],"category_scores_gemma":[0.01859774,0.0004779887,0.002074484,0.0024571666,0.00080847455,0.0006761527,0.0011837392,0.0013970827,0.00012045744],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068052467,0.00063053175,0.029668495,0.0019049409,0.0021795095,0.0005506502,0.00024143877,0.8749014,0.0006802548,0.01893583,0.009626389,0.053875387],"study_design_scores_gemma":[0.0032493474,0.0019611581,0.034472913,0.00086921477,0.0022093782,0.00030807115,0.00075231656,0.93367857,0.00071557396,0.006669918,0.014929902,0.00018362692],"about_ca_topic_score_codex":0.9516772,"about_ca_topic_score_gemma":0.93622786,"teacher_disagreement_score":0.112993225,"about_ca_system_score_codex":0.112993225,"about_ca_system_score_gemma":0.10440991,"threshold_uncertainty_score":0.8198271},"labels":[],"label_agreement":null},{"id":"W2744741417","doi":"10.1007/s41669-017-0049-9","title":"Direct Mapping of the QLQ-C30 to EQ-5D Preferences: A Comparison of Regression Methods","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Statistics; Logistic regression; Ordinary least squares; Regression diagnostic; Regression analysis; Segmented regression; Censored regression model; Regression; Mathematics; Econometrics; Local regression; Cross-sectional regression; Linear regression; Polynomial regression","score_opus":0.8025354787775343,"score_gpt":0.6055012823377216,"score_spread":0.19703419643981268,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2744741417","genre_codex":"methods","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.20560932,0.00820988,0.7769536,0.0009064723,0.00021323666,0.000674297,0.0018019524,0.0016441965,0.003986997],"genre_scores_gemma":[0.6005578,0.005821693,0.38481256,0.00027941115,0.00017999446,0.0015124888,0.002436441,0.001179427,0.0032201044],"study_design_codex":"design_other","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.97773725,0.017742654,0.00072786893,0.0019004979,0.0016622917,0.00022946658],"domain_scores_gemma":[0.91857624,0.07275154,0.0024621354,0.0027767378,0.0032184161,0.00021489558],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.033925824,0.0016668855,0.0015887665,0.0034942597,0.0002924025,0.0013095496,0.0018838932,0.0010355716,0.0044688997],"category_scores_gemma":[0.086477086,0.00070584303,0.0027084358,0.0038442488,0.0004345356,0.0016425741,0.002227136,0.0021245163,0.0015947768],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031359023,0.00054093305,0.07005507,0.0016914746,0.0033492541,0.00014080688,0.0006356928,0.21781912,0.0013621548,0.0063291835,0.0034539993,0.6914864],"study_design_scores_gemma":[0.00038560922,0.0011633013,0.04880038,0.00044630165,0.0006038904,0.0002762864,0.0004385901,0.93636507,0.0018046633,0.005692889,0.003867148,0.0001559322],"about_ca_topic_score_codex":0.006881376,"about_ca_topic_score_gemma":0.003278991,"teacher_disagreement_score":0.96607417,"about_ca_system_score_codex":0.00090091786,"about_ca_system_score_gemma":0.00090644223,"threshold_uncertainty_score":0.17941898},"labels":[],"label_agreement":null},{"id":"W2748882349","doi":"10.1007/s41669-017-0053-0","title":"Healthcare Resource Uses and Out-of-Pocket Expenses Associated with Pulmonary TB Treatment in Thailand","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Tuberculosis Research and Epidemiology","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; Impact","funders":"","keywords":"Medicine; Confidence interval; Health care; Pharmaceutical care; Pulmonary tuberculosis; Public health; Retrospective cohort study; Tuberculosis; Family medicine; Emergency medicine; Internal medicine; Nursing; Pharmacy","score_opus":0.13414114809899066,"score_gpt":0.4376703003657257,"score_spread":0.30352915226673505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2748882349","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99688786,0.0006929998,0.000098781384,0.00011687566,0.0000046008263,0.000012381923,0.0016241999,0.0000024484907,0.00055974297],"genre_scores_gemma":[0.9985781,0.00040682202,0.00007030471,0.000027306734,0.0000071867853,0.00001728635,0.0007965063,0.0000014739246,0.00009493702],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99853384,0.0005227528,0.00035856257,0.00016445022,0.0002423769,0.00017801125],"domain_scores_gemma":[0.99608,0.00067480776,0.0026002526,0.00006877058,0.00025741901,0.0003187784],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005496277,0.00028784308,0.00025787755,0.0011345289,0.0003303854,0.0011045755,0.00031592415,0.00029519372,0.0013423689],"category_scores_gemma":[0.0030918166,0.00024070665,0.0007555352,0.0025255375,0.00033763435,0.00064975425,0.0007650987,0.00071341114,0.000099975114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000077136596,0.000031098785,0.99725527,0.000066695524,0.00008685862,0.00021950297,0.00012543333,0.00045109366,0.000040124065,0.000035781886,0.00014220184,0.001468822],"study_design_scores_gemma":[0.000004397399,0.000067647445,0.9967982,0.000060506267,0.00004084559,0.00062847993,0.0008519571,0.0011887028,0.000056353045,0.000049264017,0.00024372891,0.000009920557],"about_ca_topic_score_codex":0.022900812,"about_ca_topic_score_gemma":0.017058928,"teacher_disagreement_score":0.022900812,"about_ca_system_score_codex":0.0016229616,"about_ca_system_score_gemma":0.00086211105,"threshold_uncertainty_score":0.045535028},"labels":[],"label_agreement":null},{"id":"W2752473968","doi":"10.1007/s41669-017-0051-2","title":"The Potential Clinical and Economic Value of Primary Tumour Identification in Metastatic Cancer of Unknown Primary Tumour: A Population-Based Retrospective Matched Cohort Study","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Cancer Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Michael's Hospital; University of Toronto; Cancer Care Ontario; University of Manitoba; Western University","funders":"Canadian Institutes of Health Research","keywords":"Medicine; Hazard ratio; Retrospective cohort study; Cancer; Confidence interval; Propensity score matching; Internal medicine; Cohort; Primary tumor; Proportional hazards model; Cancer registry; Population; Oncology; Clinical trial; Surgery; Metastasis","score_opus":0.039770071195847176,"score_gpt":0.4071142063706688,"score_spread":0.3673441351748216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752473968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99850404,0.0002780484,0.00020718189,0.00007076828,0.000008634192,0.000033020428,0.0005966059,0.0000022162028,0.00029948933],"genre_scores_gemma":[0.99928325,0.00010178723,0.00012574476,0.00003653307,0.000013010548,0.00001840084,0.00035639133,0.0000015567274,0.00006336994],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9982482,0.000635963,0.00014999746,0.00047033333,0.00028713333,0.00020836391],"domain_scores_gemma":[0.9964431,0.00062819856,0.0015857698,0.00064313685,0.00031264278,0.00038710271],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0031174482,0.0003101465,0.0004718605,0.0010871015,0.00065064756,0.00083247246,0.0007132683,0.0005383416,0.0013541578],"category_scores_gemma":[0.006866395,0.00040300027,0.0008706934,0.0016617965,0.0004561648,0.00053566,0.00063017977,0.00060690433,0.00019166617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00035550838,0.00003729704,0.99840444,0.000009034074,0.0001614212,0.00009933762,0.000032127537,0.00005597155,0.00007799345,0.00005164875,0.00009144117,0.0006237985],"study_design_scores_gemma":[0.000078182,0.00033571137,0.9969438,0.000016268697,0.00026359738,0.0005651348,0.00012562469,0.0010280467,0.000099391145,0.00009637869,0.00043813194,0.000009706167],"about_ca_topic_score_codex":0.012974637,"about_ca_topic_score_gemma":0.013158062,"teacher_disagreement_score":0.012974637,"about_ca_system_score_codex":0.0010095633,"about_ca_system_score_gemma":0.0008571343,"threshold_uncertainty_score":0.025798261},"labels":[],"label_agreement":null},{"id":"W2755337532","doi":"10.1007/s41669-017-0057-9","title":"Out-of-Pocket Expenditures, Indirect Costs and Health-Related Quality of Life of Patients with Pulmonary Tuberculosis in Thailand","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Tuberculosis Research and Epidemiology","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; Impact","funders":"","keywords":"Medicine; Health care; Pharmacist; Tuberculosis; Indirect costs; Family medicine; Pulmonary tuberculosis; Total cost; Emergency medicine; Pharmacy","score_opus":0.10154513704508793,"score_gpt":0.41883768569945967,"score_spread":0.31729254865437173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2755337532","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99918395,0.00018337551,0.00002259059,0.000048925347,0.0000016557847,0.0000038846406,0.00032953246,6.7708226e-7,0.0002253876],"genre_scores_gemma":[0.9995253,0.00013222551,0.000030982803,0.000015210669,0.0000031466946,0.0000075177873,0.00022552094,4.7771454e-7,0.000059742513],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9995004,0.0001880761,0.0000948924,0.000058636,0.00006707269,0.00009098904],"domain_scores_gemma":[0.99776626,0.00035195012,0.0013618565,0.00005011029,0.00014513894,0.00032470183],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00048573723,0.00023628514,0.00023550108,0.0005651259,0.00038103882,0.0008774106,0.00024388423,0.0002793177,0.0013629892],"category_scores_gemma":[0.0020894352,0.00019442568,0.0003930885,0.0013095028,0.00028294872,0.0005251707,0.000581722,0.0006336467,0.000114966264],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00006589969,0.000036400343,0.9983931,0.000020408617,0.000030628406,0.00008723165,0.00013603042,0.00008929774,0.000026759906,0.000010463193,0.000074999,0.0010287506],"study_design_scores_gemma":[0.0000064563615,0.000086898115,0.9982893,0.000019164077,0.000018691724,0.00026805053,0.0008380354,0.00030839804,0.000022231461,0.000025296029,0.000112794354,0.000004646996],"about_ca_topic_score_codex":0.010466977,"about_ca_topic_score_gemma":0.01053491,"teacher_disagreement_score":0.010466977,"about_ca_system_score_codex":0.0006344897,"about_ca_system_score_gemma":0.00050938805,"threshold_uncertainty_score":0.020812094},"labels":[],"label_agreement":null},{"id":"W2765486768","doi":"10.1007/s41669-018-0088-x","title":"International HTA Experience with Targeted Therapy Approvals for Lung Cancer","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Griffith University; Cardiff University","keywords":"Lung cancer; Medicine; Targeted therapy; Intensive care medicine; Oncology; Medical physics; Cancer; Internal medicine","score_opus":0.4290643303047238,"score_gpt":0.5516916771965357,"score_spread":0.12262734689181187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2765486768","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.74080056,0.07419338,0.011468294,0.0202508,0.000672505,0.0006234513,0.0019451858,0.000208196,0.14983772],"genre_scores_gemma":[0.97274154,0.015319563,0.0034098192,0.0017408271,0.00038937325,0.00008435026,0.0008200366,0.000040496405,0.0054539787],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98594564,0.0074785217,0.0011839969,0.0009887798,0.003369336,0.0010337164],"domain_scores_gemma":[0.926192,0.038246594,0.016385436,0.0033582407,0.009518622,0.0062991525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.023763932,0.0002778293,0.00042151843,0.0015217563,0.00073820376,0.002777642,0.00064725854,0.0008329223,0.007415561],"category_scores_gemma":[0.047053292,0.00020807108,0.0008049764,0.0028206687,0.0014018927,0.0015215455,0.00175236,0.0019264907,0.0004361248],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032264038,0.0013892533,0.32214335,0.0026175627,0.0008940716,0.0020658183,0.0072846427,0.006611554,0.0020501232,0.024326887,0.020094931,0.6072954],"study_design_scores_gemma":[0.0006388514,0.0067146076,0.6432367,0.0033320747,0.0013314749,0.009449304,0.005757742,0.0045001656,0.006256143,0.0037687563,0.3147889,0.00022525259],"about_ca_topic_score_codex":0.01996151,"about_ca_topic_score_gemma":0.023111507,"teacher_disagreement_score":0.023763932,"about_ca_system_score_codex":0.0057816254,"about_ca_system_score_gemma":0.0072140894,"threshold_uncertainty_score":0.12567723},"labels":[],"label_agreement":null},{"id":"W2766103705","doi":"10.1007/s41669-018-0112-1","title":"Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Bristol-Myers Squibb (Canada); McGill University","funders":"Bristol-Myers Squibb Canada; Bristol-Myers Squibb","keywords":"Ipilimumab; Nivolumab; Medicine; Pembrolizumab; Regimen; Internal medicine; Oncology; Progression-free survival; Cost effectiveness; Immunotherapy; Cancer; Chemotherapy","score_opus":0.023948478740535926,"score_gpt":0.33105219360357485,"score_spread":0.30710371486303895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766103705","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9252044,0.021202482,0.0046829623,0.006718825,0.00019735337,0.00195745,0.010741552,0.000099738165,0.029195266],"genre_scores_gemma":[0.9939322,0.0019761196,0.0014052566,0.00023895841,0.000016054702,0.000117161064,0.001165244,0.0000070450724,0.0011420209],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9980323,0.0010148569,0.00006266383,0.0001099581,0.0003501139,0.0004300727],"domain_scores_gemma":[0.99675447,0.0013523673,0.00034990147,0.00005904746,0.00095260696,0.00053152704],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0029970063,0.0010698473,0.0010982,0.0012139302,0.000931222,0.0021114764,0.0013945079,0.0009284862,0.0030348066],"category_scores_gemma":[0.008978849,0.0004583153,0.0017270016,0.0018130807,0.0006920106,0.0005757004,0.0009521654,0.0012669511,0.00010432986],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0102560185,0.0010854603,0.05043305,0.0025794092,0.0033993353,0.00064452033,0.00015699079,0.87397885,0.00083978684,0.009136858,0.007369166,0.04012052],"study_design_scores_gemma":[0.0055424715,0.0032312507,0.048384327,0.0009891841,0.0038206526,0.00036960383,0.00079314323,0.9216709,0.0010523056,0.0030052033,0.010983925,0.00015711825],"about_ca_topic_score_codex":0.9235267,"about_ca_topic_score_gemma":0.908836,"teacher_disagreement_score":0.08331508,"about_ca_system_score_codex":0.08331508,"about_ca_system_score_gemma":0.066505216,"threshold_uncertainty_score":0.60449606},"labels":[],"label_agreement":null},{"id":"W2766253633","doi":"10.1007/s41669-017-0061-0","title":"The Healthcare Cost Burden of Acute Myocardial Infarction in Alberta, Canada","year":2017,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Acute Myocardial Infarction Research","field":"Medicine","cited_by":33,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Canadian VIGOUR Centre; Institute of Health Economics; Alberta Hospital Edmonton; University of Alberta Hospital; University of Alberta","funders":"","keywords":"Medicine; Health care; Ambulatory care; Ambulatory; Emergency medicine; Acute care; Myocardial infarction; Population; Liberian dollar; Total cost; Medical emergency; Inpatient care; Environmental health; Business; Finance; Internal medicine","score_opus":0.04275009629830681,"score_gpt":0.397792840425913,"score_spread":0.35504274412760617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766253633","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.86673,0.03300744,0.0009328257,0.014186802,0.000389327,0.00020978432,0.056678854,0.00016814018,0.027696861],"genre_scores_gemma":[0.9713867,0.009712314,0.0010388378,0.0010100979,0.00013199885,0.00004342536,0.013600517,0.000019171892,0.0030569881],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99833834,0.00012077312,0.00009227185,0.00010027942,0.0009090011,0.00043930858],"domain_scores_gemma":[0.9978496,0.000113517584,0.00039230048,0.000030099369,0.0011666315,0.00044784823],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00080432696,0.00041027516,0.00036932636,0.0023508475,0.0014987056,0.001999947,0.001407063,0.00040270612,0.0026386469],"category_scores_gemma":[0.003305544,0.00022860912,0.0005807553,0.0064526647,0.0005455758,0.0004133581,0.0009623239,0.0008027729,0.00020780819],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002346516,0.00007366542,0.925476,0.00042514154,0.00030762763,0.0003690616,0.00038544912,0.0020710116,0.00025286397,0.0010732467,0.025549425,0.043781817],"study_design_scores_gemma":[0.00003646689,0.000022985016,0.9924412,0.0002238726,0.00010384596,0.00013013034,0.0006165678,0.0013871359,0.0000489309,0.00015137681,0.004818333,0.000019047742],"about_ca_topic_score_codex":0.9972681,"about_ca_topic_score_gemma":0.9976186,"teacher_disagreement_score":0.053198427,"about_ca_system_score_codex":0.053198427,"about_ca_system_score_gemma":0.069301054,"threshold_uncertainty_score":0.3859834},"labels":[],"label_agreement":null},{"id":"W2801866300","doi":"10.1007/s41669-018-0083-2","title":"Developing Accessible, Pictorial Versions of Health-Related Quality-of-Life Instruments Suitable for Economic Evaluation: A Report of Preliminary Studies Conducted in Canada and the United Kingdom","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; International Collaboration On Repair Discoveries; Simon Fraser University; Vancouver Coastal Health","funders":"National Institute for Health and Care Research; Ontario Stroke Network; SFU Community Trust Endowment Fund; Health Technology Assessment Programme; Simon Fraser University; Tavistock Trust for Aphasia; EuroQol Research Foundation; Research for Patient Benefit Programme; Ontario Ministry of Health and Long-Term Care","keywords":"Valuation (finance); Preference; Process (computing); Quality of life (healthcare); Psychology; Conceptual framework; Quality (philosophy); Applied psychology; Computer science; Medicine; Nursing; Business; Sociology; Social science","score_opus":0.6861002413643779,"score_gpt":0.5569994370974879,"score_spread":0.12910080426688997,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2801866300","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.626901,0.02378295,0.23751809,0.0073864297,0.00048301727,0.026805202,0.022609143,0.00041030537,0.054103952],"genre_scores_gemma":[0.55546093,0.009731197,0.4097706,0.00096328696,0.00006913619,0.011896326,0.008928985,0.00020555237,0.002974014],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.94577587,0.02730341,0.0077197407,0.001204965,0.01693026,0.0010657648],"domain_scores_gemma":[0.8546043,0.08974557,0.009429361,0.006448074,0.038715117,0.001057492],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.09218862,0.0007304052,0.0008430869,0.0042973123,0.0011838773,0.004798771,0.0011597411,0.0010168556,0.0032714894],"category_scores_gemma":[0.18618776,0.0005485015,0.001731603,0.007044991,0.0019329784,0.0025335997,0.0025809202,0.002148524,0.0005450761],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016002741,0.0009654998,0.09670766,0.004703368,0.0004159384,0.00069892197,0.014449801,0.008018443,0.0032716664,0.021480775,0.013182975,0.83450466],"study_design_scores_gemma":[0.000938716,0.0032318472,0.777078,0.009147591,0.0006711033,0.0017424112,0.016326554,0.012184204,0.012911822,0.01163033,0.15344556,0.0006918635],"about_ca_topic_score_codex":0.11346598,"about_ca_topic_score_gemma":0.15153699,"teacher_disagreement_score":0.11346598,"about_ca_system_score_codex":0.010413801,"about_ca_system_score_gemma":0.014752276,"threshold_uncertainty_score":0.48754585},"labels":[],"label_agreement":null},{"id":"W2887988025","doi":"10.1007/s41669-018-0089-9","title":"Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Schizophrenia research and treatment","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Pharmaceuticals; Janssen Scientific Affairs","keywords":"Paliperidone Palmitate; Medicaid; Paliperidone; Schizophrenia (object-oriented programming); Medicine; Pharmacy; Medical costs; Health care; Emergency medicine; Demography; Psychiatry; Family medicine; Antipsychotic; Political science","score_opus":0.058909682300852355,"score_gpt":0.3706249907799557,"score_spread":0.31171530847910334,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2887988025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9995334,0.00006720898,0.000011449201,0.000039016315,0.0000019573588,0.000004806341,0.0002631539,0.0000010601314,0.0000778813],"genre_scores_gemma":[0.99926263,0.000070413924,0.000034082143,0.000042856795,0.000004176654,0.000012058515,0.00048692312,7.2590854e-7,0.000086179105],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99949217,0.000107522705,0.00008739825,0.000081811755,0.00010748416,0.00012355173],"domain_scores_gemma":[0.99893063,0.00010076546,0.0006735213,0.000040427545,0.0000814495,0.00017315926],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00082181214,0.00018699639,0.00032226226,0.00071904226,0.0005407788,0.00053894485,0.00030955247,0.000502817,0.0009260305],"category_scores_gemma":[0.002288771,0.0002088566,0.0007820309,0.00096916687,0.00017033775,0.00049324543,0.00057913625,0.00075487955,0.00011148606],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00015148899,0.00009668132,0.9983798,0.0000057758825,0.000052419142,0.000014922083,0.0000570088,0.00005465923,0.00004987984,0.0000073905817,0.00006857164,0.0010613855],"study_design_scores_gemma":[0.000008082288,0.000067335925,0.9995189,0.000006295435,0.000019404957,0.000020667978,0.00010643738,0.00019552668,0.000013840576,0.0000056912336,0.00003564553,0.000002191809],"about_ca_topic_score_codex":0.055956207,"about_ca_topic_score_gemma":0.061272815,"teacher_disagreement_score":0.055956207,"about_ca_system_score_codex":0.0009849708,"about_ca_system_score_gemma":0.0007118253,"threshold_uncertainty_score":0.11126101},"labels":[],"label_agreement":null},{"id":"W2890017653","doi":"10.1007/s41669-018-0092-1","title":"The Psychometric Properties of a Self-Administered, Open-Source Module for Valuing Metastatic Epidural Spinal Cord Compression Utilities","year":2018,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute for Clinical Evaluative Sciences; Ottawa Hospital; University of Ottawa","funders":"","keywords":"Spinal cord compression; Medicine; Compression (physics); Spinal cord; Psychology; Psychiatry; Materials science","score_opus":0.5773868384838766,"score_gpt":0.5226113793229547,"score_spread":0.05477545916092197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2890017653","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941911,0.00011104908,0.0017968322,0.00011867742,0.000016235976,0.00047314088,0.0006879834,0.00006336552,0.0025415618],"genre_scores_gemma":[0.995146,0.000101289465,0.0031007153,0.00006175065,0.000015346082,0.0003140979,0.0007935235,0.000010889819,0.0004563674],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960847,0.001581776,0.0003931322,0.00025234645,0.0014731518,0.00021487148],"domain_scores_gemma":[0.97449476,0.014225642,0.004611544,0.001657536,0.003976192,0.0010342089],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009668462,0.00036370032,0.0003347177,0.0009681443,0.00029947184,0.000913616,0.00052504207,0.00053910667,0.0036754606],"category_scores_gemma":[0.028875172,0.00018402375,0.001012438,0.0007841102,0.000406714,0.00071017037,0.00074314926,0.0004921725,0.00075422775],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00096455583,0.00096912915,0.9212525,0.00018017765,0.00025042184,0.000065865366,0.0007897045,0.00094058464,0.0010428067,0.00013254576,0.0014174976,0.07199423],"study_design_scores_gemma":[0.000088049244,0.0014094962,0.99303955,0.00009854411,0.0000732706,0.00012665593,0.00044956364,0.0023796423,0.00076532265,0.00013040799,0.001413325,0.000026061361],"about_ca_topic_score_codex":0.0037024373,"about_ca_topic_score_gemma":0.0058633927,"teacher_disagreement_score":0.009668462,"about_ca_system_score_codex":0.0010287674,"about_ca_system_score_gemma":0.0011304828,"threshold_uncertainty_score":0.05113226},"labels":[],"label_agreement":null},{"id":"W2925255986","doi":"10.1007/s41669-019-0153-0","title":"All-Male Panels and Gender Diversity of Issue Panels and Plenary Sessions at ISPOR Europe","year":2019,"lang":"en","type":"letter","venue":"PharmacoEconomics - Open","topic":"Diversity and Career in Medicine","field":"Social Sciences","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Canadian Agency for Drugs and Technologies in Health","funders":"","keywords":"Diversity (politics); Plenary session; Political science; Engineering ethics; Library science; Engineering; Computer science; Law","score_opus":0.13582559758370824,"score_gpt":0.36840176837394856,"score_spread":0.23257617079024032,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2925255986","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0050202645,0.000487183,0.0001966833,0.9597518,0.010046037,0.00005526938,0.00007250888,0.000021988479,0.024348255],"genre_scores_gemma":[0.03824366,0.00040406108,0.00019624758,0.8892406,0.011434757,0.0001414121,0.00004345031,0.0000623568,0.060233384],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9832097,0.004010733,0.00073791365,0.0014426886,0.0030399647,0.0075588664],"domain_scores_gemma":[0.9537765,0.018605094,0.0019215862,0.0008029201,0.0041922336,0.020701658],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.018017821,0.00096617185,0.0012682829,0.0009371119,0.021320283,0.011176276,0.0024247665,0.09157787,0.037449643],"category_scores_gemma":[0.040001135,0.0015142708,0.0013341302,0.0008733664,0.0034557085,0.0051757437,0.0049069887,0.04274865,0.006927499],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022524167,0.00015845012,0.003848003,0.000058541453,0.000029474919,0.0047199694,0.0011646017,0.00009945974,0.0007091976,0.010806807,0.9697823,0.008397928],"study_design_scores_gemma":[0.00030316462,0.000223939,0.016113086,0.000520974,0.00006943554,0.002933219,0.009984993,0.0008370164,0.0015329074,0.0094698565,0.95785534,0.00015592902],"about_ca_topic_score_codex":0.01368104,"about_ca_topic_score_gemma":0.03469898,"teacher_disagreement_score":0.9819822,"about_ca_system_score_codex":0.009157531,"about_ca_system_score_gemma":0.014795351,"threshold_uncertainty_score":0.12528151},"labels":[],"label_agreement":null},{"id":"W2933306415","doi":"10.1007/s41669-019-0131-6","title":"Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"Novo Nordisk","keywords":"Dulaglutide; Semaglutide; Type 2 diabetes; Medicine; Internal medicine; Diabetes mellitus; Endocrinology; Exenatide; Liraglutide","score_opus":0.04761554358127133,"score_gpt":0.33630039552377733,"score_spread":0.288684851942506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2933306415","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.94780874,0.01740701,0.003192911,0.0036507298,0.000113706985,0.0006452893,0.0071283435,0.00013055891,0.019922625],"genre_scores_gemma":[0.9946247,0.0022204474,0.0010908842,0.00024237133,0.000009326392,0.000050479583,0.00080750504,0.00001075006,0.00094341696],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9982128,0.00070853945,0.00008083741,0.00013424172,0.0004723542,0.00039133985],"domain_scores_gemma":[0.99662435,0.0016426111,0.00038341968,0.00007917777,0.0008322232,0.00043821364],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0022822449,0.0007029256,0.0011847493,0.0011586304,0.00085969194,0.0021915608,0.0015244787,0.0008917387,0.0028806385],"category_scores_gemma":[0.009317523,0.0004451732,0.0023869015,0.0016911059,0.0005160725,0.00075406354,0.0007804917,0.0011054472,0.00008930717],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01637124,0.0007184474,0.05508992,0.0016158978,0.003697185,0.0007544782,0.00019302938,0.8181928,0.0013163078,0.008397202,0.0059533697,0.08770015],"study_design_scores_gemma":[0.0061941515,0.003324438,0.104102194,0.00094235706,0.006239861,0.0004936432,0.0009674214,0.8612828,0.0017794654,0.0067373146,0.007593393,0.00034286355],"about_ca_topic_score_codex":0.94299805,"about_ca_topic_score_gemma":0.93757427,"teacher_disagreement_score":0.05700195,"about_ca_system_score_codex":0.055596825,"about_ca_system_score_gemma":0.048311718,"threshold_uncertainty_score":0.4033851},"labels":[],"label_agreement":null},{"id":"W2935761670","doi":"10.1007/s41669-019-0132-5","title":"Economic Burden and Health-Related Quality of Life Associated with Current Treatments for Anaemia in Patients with CKD not on Dialysis: A Systematic Review","year":2019,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Erythropoietin and Anemia Treatment","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Akebia Therapeutics; Otsuka Pharmaceutical","keywords":"Medicine; Observational study; Quality of life (healthcare); Cochrane Library; Randomized controlled trial; Intensive care medicine; Kidney disease; Population; MEDLINE; Dialysis; Pediatrics; Internal medicine; Environmental health","score_opus":0.1412128731212003,"score_gpt":0.4430817841296246,"score_spread":0.30186891100842433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2935761670","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0018773978,0.9972541,0.00006347782,0.00016322262,0.000047213798,0.00013333956,0.0002755479,0.0000037275938,0.00018200032],"genre_scores_gemma":[0.028520096,0.97003114,0.00038751386,0.00032882844,0.00007631277,0.00034953415,0.00022703338,0.000003550463,0.00007597264],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9941223,0.002313302,0.0019724988,0.00039141517,0.0010282238,0.0001723547],"domain_scores_gemma":[0.9702191,0.02183699,0.00580798,0.00024413408,0.001656588,0.00023530127],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0057180827,0.0011024682,0.00847036,0.008196286,0.0005126775,0.0026167238,0.0013981182,0.0015940942,0.002953732],"category_scores_gemma":[0.03269917,0.00089203444,0.0079381475,0.008393433,0.0006624524,0.0015950432,0.0010872802,0.0011539272,0.00013523537],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00034607656,0.000025341507,0.0020648509,0.9445553,0.021050459,0.00009005103,0.00012357633,0.0001342116,0.000060017934,0.00018801622,0.0011207262,0.03024121],"study_design_scores_gemma":[0.00046847333,0.00037450495,0.014248027,0.82423645,0.14589377,0.0006006849,0.0003403524,0.00023195356,0.00014724699,0.00045123498,0.012943378,0.00006400282],"about_ca_topic_score_codex":0.00839716,"about_ca_topic_score_gemma":0.019750578,"teacher_disagreement_score":0.00847036,"about_ca_system_score_codex":0.0037683018,"about_ca_system_score_gemma":0.006978326,"threshold_uncertainty_score":0.030240476},"labels":[],"label_agreement":null},{"id":"W2942619274","doi":"10.1007/s41669-019-0142-3","title":"A Systematic Review of the Health Economics of Pompe Disease","year":2019,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Audentes Therapeutics","keywords":"Medicine; Enzyme replacement therapy; Life expectancy; Disease; Quality of life (healthcare); Quality-adjusted life year; Health economics; MEDLINE; Health care; Economic evaluation; Systematic review; Indirect costs; Pediatrics; Cost effectiveness; Family medicine; Physical therapy; Environmental health; Public health; Internal medicine; Nursing; Pathology","score_opus":0.12459082680849154,"score_gpt":0.47341610194434597,"score_spread":0.34882527513585443,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2942619274","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0014353185,0.9953048,0.00026226888,0.00047889346,0.00015305392,0.0004914379,0.0012031363,0.0000094381,0.0006615666],"genre_scores_gemma":[0.020138929,0.9769071,0.00084526226,0.00055252836,0.00012289378,0.0007649738,0.00050324877,0.000009057165,0.00015605673],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9870684,0.005628559,0.0043383623,0.00066177524,0.0019471099,0.00035567512],"domain_scores_gemma":[0.95400655,0.03458475,0.0072857356,0.0005597059,0.0032535882,0.00030960137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011636853,0.0020665014,0.009170433,0.013980274,0.0006330153,0.0035853395,0.0018190995,0.0016351653,0.0069852946],"category_scores_gemma":[0.06219681,0.0010848241,0.009947115,0.011380905,0.0008125733,0.002216819,0.0016822362,0.001516241,0.00040471062],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00022747766,0.000013688639,0.00065993244,0.95545495,0.01598181,0.00011718942,0.00009657517,0.00022351269,0.00007336451,0.00042095693,0.0014049292,0.025325574],"study_design_scores_gemma":[0.00032592283,0.00016665767,0.0034636648,0.9051039,0.07510531,0.00033016794,0.00014055213,0.00013281345,0.00010434534,0.0006757184,0.01441776,0.000033285032],"about_ca_topic_score_codex":0.009080621,"about_ca_topic_score_gemma":0.01992094,"teacher_disagreement_score":0.013980274,"about_ca_system_score_codex":0.006106316,"about_ca_system_score_gemma":0.013237407,"threshold_uncertainty_score":0.061542273},"labels":[],"label_agreement":null},{"id":"W2943596749","doi":"10.1007/s41669-019-0137-0","title":"The Costs of Industry-Sponsored Medical Device Clinical Trials in Alberta","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"University of Alberta; Alberta Health Services","keywords":"Clinical trial; Business; Medical device; Medicine; Internal medicine; Biomedical engineering","score_opus":0.6781917796155964,"score_gpt":0.6814709660396648,"score_spread":0.0032791864240684365,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943596749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.63721037,0.1495871,0.010084376,0.032214332,0.001075496,0.0061588907,0.04760945,0.00044560854,0.11561447],"genre_scores_gemma":[0.9583924,0.01611896,0.00558323,0.003548592,0.000523639,0.0010835638,0.009965588,0.00004076505,0.0047433157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9515853,0.024633562,0.004151862,0.0014656212,0.014746214,0.0034174689],"domain_scores_gemma":[0.9027751,0.04858124,0.022918737,0.0025331546,0.014976388,0.008215361],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.024985494,0.0005530408,0.00076939305,0.0037097547,0.0012653858,0.004168261,0.0017254666,0.0009834981,0.0027775115],"category_scores_gemma":[0.073405854,0.00049099635,0.001059735,0.006348092,0.0016958598,0.00085908565,0.0017854866,0.0011253061,0.00020550263],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068232324,0.0005604083,0.61446124,0.004457023,0.0037315292,0.0010766351,0.0011644837,0.02057523,0.0008687495,0.017372083,0.046977617,0.28193185],"study_design_scores_gemma":[0.0022564158,0.0017143101,0.8905884,0.0031784791,0.00197913,0.0010871191,0.0018549551,0.011059577,0.00071703206,0.003953914,0.08139629,0.00021435632],"about_ca_topic_score_codex":0.6615502,"about_ca_topic_score_gemma":0.79333836,"teacher_disagreement_score":0.9750145,"about_ca_system_score_codex":0.058863487,"about_ca_system_score_gemma":0.066085644,"threshold_uncertainty_score":0.6808859},"labels":[],"label_agreement":null},{"id":"W2943673305","doi":"10.1007/s41669-019-0139-y","title":"A Comparison of Pharmaceutical Budget Impact Analysis (BIA) Recommendations Amongst the Canadian Patented Medicine Prices Review Board (PMPRB), Public and Private Payers","year":2019,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; Impact; Programs for Assessment of Technology in Health Research Institute","funders":"Mitacs","keywords":"Agency (philosophy); Population; Health care; Business; Family medicine; Medicine; Public health; Cost–benefit analysis; Private sector; Actuarial science; Accounting; Environmental health; Political science; Nursing","score_opus":0.6885709978218029,"score_gpt":0.6102526625261878,"score_spread":0.07831833529561505,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943673305","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.064578325,0.6602898,0.014868091,0.14353102,0.0025392366,0.0039868616,0.017487787,0.0003640019,0.09235478],"genre_scores_gemma":[0.44208187,0.41235036,0.07583339,0.044698443,0.0011615916,0.0045251823,0.014986775,0.00038726054,0.003975099],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.83817977,0.04975066,0.026902622,0.0033720608,0.075470895,0.00632398],"domain_scores_gemma":[0.6251366,0.18847619,0.027026683,0.0043872953,0.14924756,0.005725633],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.16431904,0.001066574,0.002287788,0.027652483,0.00260977,0.010931918,0.005174256,0.003044222,0.0017816161],"category_scores_gemma":[0.3613405,0.0014758068,0.0029347676,0.039618984,0.0017532804,0.003744266,0.002167952,0.0043821787,0.0003899061],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00088856433,0.00015220925,0.036097903,0.0396999,0.0023952979,0.00024077248,0.0054623126,0.0051210015,0.0007344806,0.030530548,0.21130143,0.6673755],"study_design_scores_gemma":[0.0008767979,0.0005016535,0.24358635,0.14381912,0.0050430093,0.00045533766,0.009099661,0.0061019394,0.0021572146,0.012293825,0.57508755,0.0009775196],"about_ca_topic_score_codex":0.6306078,"about_ca_topic_score_gemma":0.7433005,"teacher_disagreement_score":0.93067354,"about_ca_system_score_codex":0.06932646,"about_ca_system_score_gemma":0.1447551,"threshold_uncertainty_score":0.86901253},"labels":[],"label_agreement":null},{"id":"W2952476208","doi":"10.1007/s41669-019-0143-2","title":"The Health System Costs of Potentially Inappropriate Prescribing: A Population-Based, Retrospective Cohort Study Using Linked Health Administrative Databases in Ontario, Canada","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Pharmaceutical Practices and Patient Outcomes","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; Bruyère; University of Ottawa","funders":"Canadian Institutes of Health Research; University of Ottawa","keywords":"Retrospective cohort study; Medicine; Environmental health; Cohort; Population; Population health; Database; Family medicine; Business; Computer science","score_opus":0.1620565774407131,"score_gpt":0.43403084027377725,"score_spread":0.27197426283306414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2952476208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9730286,0.001262366,0.00026182723,0.00039043484,0.000017004268,0.0001617896,0.02317536,0.000021816802,0.001680722],"genre_scores_gemma":[0.99225426,0.00070979743,0.0002808823,0.00013926327,0.000011724543,0.00006441541,0.006060601,0.0000065111817,0.0004725097],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.997832,0.00017026154,0.00022854672,0.00036722518,0.00090761046,0.0004944002],"domain_scores_gemma":[0.9956092,0.0002255826,0.0017146263,0.00021254044,0.0016813646,0.00055663165],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011849931,0.0005183768,0.0006837574,0.002154527,0.0022745598,0.0016899366,0.0014481257,0.00048230696,0.0013264302],"category_scores_gemma":[0.003712117,0.00069336983,0.0010699262,0.006836162,0.00070955243,0.0006163101,0.0010924684,0.0008345064,0.00019524473],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000036888392,0.000017469385,0.99787784,0.000034464058,0.00010016695,0.000048922946,0.000206513,0.00008432941,0.000041156054,0.00003941302,0.00073652493,0.0007763157],"study_design_scores_gemma":[0.000011190776,0.000013821808,0.9986034,0.00003593278,0.000049295748,0.000050181854,0.0003325904,0.0002982268,0.000017021473,0.000012892597,0.00056685304,0.000008589452],"about_ca_topic_score_codex":0.99117637,"about_ca_topic_score_gemma":0.9930167,"teacher_disagreement_score":0.03241467,"about_ca_system_score_codex":0.03241467,"about_ca_system_score_gemma":0.030843489,"threshold_uncertainty_score":0.23518604},"labels":[],"label_agreement":null},{"id":"W2954548710","doi":"10.1007/s41669-019-0156-x","title":"The Use of Computer Simulation Modeling to Estimate Complications in Patients with Type 2 Diabetes Mellitus: Comparative Validation of the Cornerstone Diabetes Simulation Model","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Diabetes, Cardiovascular Risks, and Lipoproteins","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sanofi (Canada)","funders":"Sanofi","keywords":"Medicine; Diabetes mellitus; Absolute risk reduction; United Kingdom Prospective Diabetes Study; Type 2 diabetes; Clinical trial; Confidence interval; Internal medicine","score_opus":0.0777691001279494,"score_gpt":0.3536708675563976,"score_spread":0.2759017674284482,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2954548710","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8665475,0.0008218539,0.124880716,0.000799881,0.00011330474,0.0004912669,0.0011384138,0.0005331737,0.0046739015],"genre_scores_gemma":[0.97585857,0.00026369494,0.022691978,0.00011411933,0.000014160055,0.0002277413,0.0005632409,0.000031813976,0.00023459306],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99338174,0.0052676373,0.0003515647,0.00037938837,0.0004679253,0.00015178841],"domain_scores_gemma":[0.92180014,0.070047244,0.0020181763,0.0027298867,0.002923673,0.00048093728],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012379242,0.0008214004,0.0011012706,0.001067257,0.00028571836,0.0014597478,0.001261115,0.0012149834,0.0009662736],"category_scores_gemma":[0.05071859,0.0005792944,0.0011835741,0.00089064846,0.00046749314,0.00071858085,0.0009397271,0.001105665,0.00015669911],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011150212,0.00019933905,0.024735078,0.00011431293,0.0002788691,0.00006661045,0.0001672164,0.9569686,0.00035671674,0.0015975925,0.00033845135,0.01406222],"study_design_scores_gemma":[0.00015524932,0.00031462713,0.0033564742,0.00005119491,0.000060228416,0.00003478196,0.000046496196,0.99431807,0.00039089122,0.0009058199,0.0003415851,0.000024590492],"about_ca_topic_score_codex":0.02106458,"about_ca_topic_score_gemma":0.005754872,"teacher_disagreement_score":0.02106458,"about_ca_system_score_codex":0.0015562692,"about_ca_system_score_gemma":0.0024525824,"threshold_uncertainty_score":0.06546849},"labels":[],"label_agreement":null},{"id":"W2956056819","doi":"10.1007/s41669-019-0154-z","title":"US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Treatment of Major Depression","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Major depressive disorder; Medicine; Depression (economics); Retrospective cohort study; Cohort; Treatment-resistant depression; Internal medicine; Confidence interval; Propensity score matching; Comorbidity; Rate ratio; Psychiatry; Mood","score_opus":0.01090551635820826,"score_gpt":0.30067986308468414,"score_spread":0.2897743467264759,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2956056819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965094,0.0004178203,0.0002460384,0.00014210632,0.000012064817,0.00007117629,0.0021052556,0.0000031075242,0.0004929704],"genre_scores_gemma":[0.99773765,0.00023638763,0.00024442063,0.0001359647,0.000022720204,0.00007359086,0.001413915,0.0000023172374,0.00013299265],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99869895,0.00044023868,0.00017620793,0.00029053164,0.00018808145,0.00020595787],"domain_scores_gemma":[0.99733514,0.00023266216,0.0016873131,0.00024086083,0.00025110613,0.00025287582],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014084505,0.00031123895,0.0003902339,0.0013893342,0.0006280506,0.0008563367,0.0004726879,0.00042439034,0.0019585767],"category_scores_gemma":[0.0045454362,0.00038495098,0.0007686913,0.0025392664,0.00023018211,0.00089198264,0.00087708374,0.0006545893,0.00028342172],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000088036875,0.000044713997,0.99865484,0.000007976238,0.00011446291,0.000043642012,0.000049350318,0.000032392396,0.000024805597,0.000043309534,0.00022340416,0.0006729332],"study_design_scores_gemma":[0.00003733529,0.00021331118,0.99749726,0.000030447163,0.00013641542,0.0003382615,0.00041841684,0.00060252054,0.000034127475,0.00006956807,0.00061462185,0.000007706894],"about_ca_topic_score_codex":0.018858774,"about_ca_topic_score_gemma":0.022351747,"teacher_disagreement_score":0.018858774,"about_ca_system_score_codex":0.0010093624,"about_ca_system_score_gemma":0.00076354214,"threshold_uncertainty_score":0.037497997},"labels":[],"label_agreement":null},{"id":"W2962517794","doi":"10.1007/s41669-019-0161-0","title":"The Costs of Industry-Sponsored Drug Trials in Canada","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Pharmaceutical industry and healthcare","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"Innovative Medicines Canada","keywords":"Cancer drugs; Medicine; Clinical trial; Drug; Business; Pharmacology; Internal medicine","score_opus":0.44391710692776887,"score_gpt":0.573564349915947,"score_spread":0.1296472429881781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2962517794","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"incentives","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"incentives","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.48236084,0.10259132,0.010554937,0.05856461,0.001043044,0.0033068238,0.118456274,0.0005187195,0.22260348],"genre_scores_gemma":[0.94784516,0.019959325,0.0041654124,0.0035906848,0.00037390663,0.00048169383,0.016659545,0.00005580272,0.006868423],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97718436,0.0067990418,0.0020168086,0.00085738645,0.010580825,0.002561561],"domain_scores_gemma":[0.9483969,0.012084686,0.01514588,0.0008955615,0.01839053,0.0050863917],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.008110281,0.0004282303,0.0005053674,0.004658969,0.0013238708,0.0035039296,0.0011218678,0.0006205113,0.004107231],"category_scores_gemma":[0.050341863,0.00039009872,0.0010095071,0.007909603,0.0009480746,0.001114907,0.0014594739,0.0012901422,0.0002966102],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010733856,0.00019716767,0.66566414,0.002635067,0.0018897452,0.0006058758,0.0006719629,0.018504225,0.00033715312,0.021159068,0.10241719,0.18484508],"study_design_scores_gemma":[0.00033379265,0.00027604983,0.8508504,0.001903785,0.00085473823,0.00085425656,0.0012065775,0.014980571,0.00040440095,0.0041463375,0.12407565,0.000113383154],"about_ca_topic_score_codex":0.9254286,"about_ca_topic_score_gemma":0.9471305,"teacher_disagreement_score":0.9918897,"about_ca_system_score_codex":0.06740198,"about_ca_system_score_gemma":0.08211202,"threshold_uncertainty_score":0.48903793},"labels":[],"label_agreement":null},{"id":"W2965330563","doi":"10.1007/s41669-019-0159-7","title":"Early Economic Evaluation to Identify the Necessary Test Characteristics of a New Typhoid Test to be Cost Effective in Ghana","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Salmonella and Campylobacter epidemiology","field":"Agricultural and Biological Sciences","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"","keywords":"Typhoid fever; Widal test; Test (biology); Economic evaluation; Medicine; Decision tree; Computer science; Salmonella typhi; Artificial intelligence","score_opus":0.058734378705583644,"score_gpt":0.3704102202133898,"score_spread":0.3116758415078062,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2965330563","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8093759,0.01726274,0.117659666,0.010664896,0.00026517865,0.0050001433,0.0047420175,0.00014179487,0.034887657],"genre_scores_gemma":[0.9820123,0.0019013315,0.013503595,0.00032038736,0.000025572403,0.00047179035,0.0006646223,0.000010438098,0.0010900126],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9929739,0.0059502763,0.00013511023,0.00013733585,0.00041863005,0.0003846984],"domain_scores_gemma":[0.96348685,0.033428792,0.0012894906,0.0002680324,0.0012134969,0.00031332005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012503816,0.0007709148,0.001155641,0.0010353728,0.00024447325,0.0020448822,0.00064747385,0.0010050926,0.0066564623],"category_scores_gemma":[0.04765018,0.00041238728,0.0015820361,0.0009763783,0.0005146791,0.0018840625,0.0007821017,0.0016657503,0.00022952838],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009296509,0.000842143,0.034322478,0.0030695999,0.0012370576,0.0011314455,0.00024870824,0.8038918,0.0018297771,0.033338264,0.005184472,0.10560779],"study_design_scores_gemma":[0.0016227509,0.004420656,0.040986333,0.0019360112,0.0019658415,0.00066367944,0.001080729,0.8969139,0.0030486952,0.031312108,0.015934827,0.000114450595],"about_ca_topic_score_codex":0.008095545,"about_ca_topic_score_gemma":0.005106406,"teacher_disagreement_score":0.012503816,"about_ca_system_score_codex":0.0063674822,"about_ca_system_score_gemma":0.004576155,"threshold_uncertainty_score":0.0661273},"labels":[],"label_agreement":null},{"id":"W2975748077","doi":"10.1007/s41669-019-00180-z","title":"Economic Evaluation of Azacitidine in Elderly Patients with Acute Myeloid Leukemia with High Blast Counts","year":2019,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Azacitidine; Medicine; Myeloid leukemia; Cost effectiveness; Internal medicine; Oncology; Cytarabine; Population; Hypomethylating agent; Environmental health; DNA methylation","score_opus":0.02051727135984825,"score_gpt":0.3295631370827624,"score_spread":0.30904586572291415,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2975748077","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9376123,0.011914662,0.018603593,0.004304462,0.0001847447,0.0014960896,0.0051585,0.000068503155,0.020657169],"genre_scores_gemma":[0.9953733,0.0011697649,0.0018277507,0.0001387358,0.000019254605,0.00012712828,0.0006563645,0.0000046144382,0.0006831665],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.998271,0.0011948107,0.000052472344,0.000099078374,0.00016217849,0.00022038676],"domain_scores_gemma":[0.995188,0.0036899184,0.00041053985,0.00007299011,0.00028566457,0.0003528496],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004209857,0.0008737086,0.0013270032,0.00085241726,0.00048256788,0.001678869,0.0010314829,0.0013523625,0.0037126797],"category_scores_gemma":[0.012876396,0.0005935998,0.0022484837,0.00095803343,0.000586955,0.0008666959,0.0007906137,0.0015795557,0.00013648068],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004293531,0.0003706985,0.0204085,0.000720158,0.00116638,0.00047658925,0.000063708765,0.9486625,0.00040482683,0.0067718616,0.0017046164,0.014956628],"study_design_scores_gemma":[0.0014237186,0.0021437185,0.017607005,0.0004807603,0.0017031257,0.00033284025,0.0002305462,0.9667831,0.00046774227,0.005540993,0.0032187307,0.00006775092],"about_ca_topic_score_codex":0.08067029,"about_ca_topic_score_gemma":0.046380565,"teacher_disagreement_score":0.08067029,"about_ca_system_score_codex":0.010500114,"about_ca_system_score_gemma":0.008284963,"threshold_uncertainty_score":0.16040146},"labels":[],"label_agreement":null},{"id":"W3010862135","doi":"10.1007/s41669-020-00204-z","title":"Cost-Effectiveness Analyses, Costs and Resource Use, and Health-Related Quality of Life in Patients with Follicular or Marginal Zone Lymphoma: Systematic Reviews","year":2020,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bell (Canada)","funders":"Janssen Pharmaceuticals","keywords":"Medicine; Rituximab; Follicular lymphoma; Cost effectiveness; Obinutuzumab; Systematic review; MEDLINE; Quality-adjusted life year; Bendamustine; Oncology; Internal medicine; Lymphoma","score_opus":0.32936076707084955,"score_gpt":0.47322178850499214,"score_spread":0.1438610214341426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3010862135","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009717442,0.9974433,0.00014556458,0.00024641346,0.00009346291,0.00027265807,0.00057942246,0.00000883461,0.00023853482],"genre_scores_gemma":[0.030667279,0.9658124,0.0012463693,0.00059171295,0.00013848468,0.0010288192,0.00038992395,0.000012857727,0.000112083726],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9796578,0.009254867,0.00705942,0.0010568303,0.0025424215,0.00042878065],"domain_scores_gemma":[0.9262833,0.0574201,0.011339295,0.00073540106,0.0038788836,0.00034297848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016607633,0.0020162428,0.0116349235,0.014016709,0.0004663886,0.003764285,0.0019262569,0.002211639,0.004556438],"category_scores_gemma":[0.08774619,0.0015954913,0.016256995,0.013382345,0.00090140506,0.0024494682,0.0015058647,0.0019932806,0.00025889202],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031269685,0.000017666809,0.00072226115,0.9462764,0.029982615,0.000052767547,0.00007417383,0.00026135097,0.00006133695,0.0002518842,0.0010796523,0.02090711],"study_design_scores_gemma":[0.0007361627,0.00030121303,0.0054078638,0.7825733,0.19645436,0.00037233887,0.00022068743,0.0003068474,0.00016444623,0.00076695724,0.012637061,0.000058782753],"about_ca_topic_score_codex":0.009145994,"about_ca_topic_score_gemma":0.021676742,"teacher_disagreement_score":0.016607633,"about_ca_system_score_codex":0.0058861556,"about_ca_system_score_gemma":0.009470014,"threshold_uncertainty_score":0.0878306},"labels":[],"label_agreement":null},{"id":"W3015688173","doi":"10.1007/s41669-020-00212-z","title":"Do Rural Residents in China Understand EQ-5D-5L as Intended? Evidence From a Qualitative Study","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Tianjin University; National Natural Science Foundation of China","keywords":"Anxiety; CLARITY; Relevance (law); Qualitative research; Psychology; China; Mental health; Population; Clinical psychology; Gerontology; Medicine; Psychiatry; Environmental health; Geography; Sociology; Social science; Political science","score_opus":0.6214977604419405,"score_gpt":0.5467421121684448,"score_spread":0.07475564827349568,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3015688173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99175245,0.001281826,0.0011622114,0.0023498114,0.0000442104,0.0004887696,0.00035259442,0.000011467804,0.0025565885],"genre_scores_gemma":[0.99374455,0.0013638157,0.001113065,0.0013660617,0.000013543468,0.0010431225,0.0001700911,0.000015906384,0.0011698122],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9923224,0.0053150402,0.0003192776,0.00046001672,0.0006187121,0.00096464524],"domain_scores_gemma":[0.9823262,0.01357498,0.00126761,0.00037531854,0.001518736,0.00093713246],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.01708824,0.0005361144,0.0009630761,0.001642707,0.004407968,0.0017425963,0.0014654374,0.0010045436,0.0035855288],"category_scores_gemma":[0.022860583,0.0007076919,0.0005916325,0.0021497274,0.0038516717,0.0029871275,0.0031201208,0.0015699861,0.00029456764],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00004921953,0.000047006153,0.011936525,0.00076733984,0.000011117128,0.00085778476,0.97834253,0.00003079965,0.00042857937,0.00055237743,0.0005138898,0.0064628543],"study_design_scores_gemma":[0.000009716906,0.00008052837,0.008600976,0.0007390876,0.000011850113,0.00019763265,0.9855203,0.000097333825,0.00011988604,0.00019754937,0.004405363,0.000019784413],"about_ca_topic_score_codex":0.027671296,"about_ca_topic_score_gemma":0.032515507,"teacher_disagreement_score":0.98291177,"about_ca_system_score_codex":0.0069058915,"about_ca_system_score_gemma":0.009985423,"threshold_uncertainty_score":0.090372324},"labels":[],"label_agreement":null},{"id":"W3016073506","doi":"10.1007/s41669-020-00215-w","title":"Fall/Fracture-Related Healthcare Costs and Their Association with Cumulative Anticholinergic Burden in People with Overactive Bladder","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health","funders":"Astellas Pharma Global Development; Astellas Pharma","keywords":"Anticholinergic; Medicine; Cohort; Overactive bladder; Emergency medicine; Cohort study; Health care; Anticholinergic agents; Physical therapy; Internal medicine; Alternative medicine","score_opus":0.030604975134650107,"score_gpt":0.35366453399302655,"score_spread":0.32305955885837645,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016073506","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99789906,0.00057104893,0.000057880938,0.00011696743,0.0000052080773,0.000011423168,0.0009931873,0.000002119524,0.0003431341],"genre_scores_gemma":[0.9989856,0.00023354111,0.000085281594,0.000018602224,0.000011410049,0.000011992574,0.0005926848,8.757533e-7,0.00006000601],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9994185,0.00013873869,0.00011645137,0.00007416939,0.00013509534,0.00011711035],"domain_scores_gemma":[0.9972326,0.00043554974,0.0016140089,0.00009592266,0.00032778602,0.00029417488],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008570877,0.00027249916,0.000379836,0.0013929649,0.00038230812,0.00067312666,0.00045905882,0.00047171343,0.0018580651],"category_scores_gemma":[0.0049506584,0.00028191792,0.0012800022,0.0018568195,0.00018605094,0.0005931844,0.00078177196,0.0007890493,0.0001714739],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000043353015,0.00001625645,0.9991561,0.000009591004,0.000061337225,0.000015981583,0.000018009787,0.000065915956,0.000007978202,0.000009262672,0.00004815125,0.00054814323],"study_design_scores_gemma":[0.0000029734354,0.000025143898,0.9994103,0.000009842342,0.000027394099,0.00006725463,0.000066642206,0.00030704454,0.000005853303,0.000026567206,0.00004898448,0.0000021008964],"about_ca_topic_score_codex":0.018392202,"about_ca_topic_score_gemma":0.019907119,"teacher_disagreement_score":0.018392202,"about_ca_system_score_codex":0.00061528006,"about_ca_system_score_gemma":0.00045315654,"threshold_uncertainty_score":0.03657031},"labels":[],"label_agreement":null},{"id":"W3089359485","doi":"10.1007/s41669-020-00231-w","title":"Systematic Literature Review of Economic Evaluations, Costs/Resource Use, and Quality of Life in Patients with Mantle Cell Lymphoma","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Bell (Canada)","funders":"Janssen Pharmaceuticals","keywords":"EconLit; MEDLINE; Medicine; Systematic review; Economic evaluation; Quality of life (healthcare); Cochrane Library; Mantle cell lymphoma; Resource (disambiguation); Family medicine; Meta-analysis; Lymphoma; Political science; Pathology; Computer science","score_opus":0.044622184933162896,"score_gpt":0.3441055139569483,"score_spread":0.2994833290237854,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3089359485","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0019391552,0.99492186,0.00027155934,0.00056601927,0.00015902866,0.0006142018,0.00092686986,0.000011977806,0.00058936875],"genre_scores_gemma":[0.031014815,0.96452576,0.0012059757,0.00092187204,0.00014864666,0.0014924133,0.0005382601,0.000013143098,0.0001390315],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.97060794,0.014109471,0.010146963,0.0010697095,0.0035125872,0.00055336143],"domain_scores_gemma":[0.8946622,0.08304205,0.014804325,0.0009485726,0.0059075328,0.0006351738],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.022703534,0.002099604,0.010706937,0.018482063,0.0008036937,0.0044702324,0.0024551444,0.0025442154,0.0059250277],"category_scores_gemma":[0.12536283,0.0013867023,0.010765005,0.016304374,0.0011772285,0.0034707633,0.002193259,0.002110979,0.00031323425],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00025816626,0.0000197392,0.00086562784,0.9606392,0.012327805,0.0001146957,0.00012840104,0.00019042214,0.00004466815,0.00031836805,0.0012529674,0.023839932],"study_design_scores_gemma":[0.0003211448,0.00020084216,0.003155922,0.9297496,0.055614218,0.00033824678,0.00025402824,0.00017091872,0.00008720238,0.0005414371,0.009526533,0.000039904327],"about_ca_topic_score_codex":0.008950052,"about_ca_topic_score_gemma":0.021479398,"teacher_disagreement_score":0.022703534,"about_ca_system_score_codex":0.00898568,"about_ca_system_score_gemma":0.016300589,"threshold_uncertainty_score":0.120069146},"labels":[],"label_agreement":null},{"id":"W3097148862","doi":"10.1007/s41669-020-00235-6","title":"Investigation of Factors Considered by Health Technology Assessment Agencies in Eight Countries","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Pharmacoeconomics; Health technology; Excellence; Economic evaluation; Nice; Medicine; Health economics; Health care; Stakeholder; Transparency (behavior); Family medicine; Economic growth; Political science; Public relations; Economics; Intensive care medicine","score_opus":0.5166002091916603,"score_gpt":0.5059722978757282,"score_spread":0.010627911315932104,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3097148862","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96751493,0.0039304653,0.0012695245,0.0065094964,0.000057532125,0.0006648456,0.0010385398,0.000027250138,0.018987259],"genre_scores_gemma":[0.9976459,0.0005694691,0.0008854563,0.00040501333,0.000014489443,0.00014080603,0.00015432281,0.0000052476234,0.00017923198],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9015221,0.06199946,0.014919276,0.0025690775,0.013232509,0.0057575814],"domain_scores_gemma":[0.6415209,0.23359728,0.069725126,0.0052160765,0.043441825,0.0064987848],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0676342,0.00044312194,0.0006863801,0.008050374,0.0030051658,0.008444929,0.0010921817,0.0015752765,0.002505338],"category_scores_gemma":[0.18265346,0.00046850424,0.0015313515,0.013061679,0.0025618016,0.0029298645,0.0043131863,0.001761329,0.000176558],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010799887,0.00039078822,0.85796267,0.0025577792,0.0007340806,0.0010090141,0.032150667,0.002816247,0.0005065654,0.01001904,0.0033189168,0.08745423],"study_design_scores_gemma":[0.00018299729,0.0011011906,0.826179,0.0030865455,0.0006614585,0.0008309876,0.12875669,0.003417376,0.0012582379,0.0029498488,0.03137347,0.00020219939],"about_ca_topic_score_codex":0.01626943,"about_ca_topic_score_gemma":0.007984175,"teacher_disagreement_score":0.9323658,"about_ca_system_score_codex":0.017464317,"about_ca_system_score_gemma":0.013382464,"threshold_uncertainty_score":0.35768813},"labels":[],"label_agreement":null},{"id":"W3103580978","doi":"10.1007/s41669-020-00241-8","title":"The Actual Operative Costs of Liver Transplantation and Normothermic Machine Perfusion in a Canadian Setting","year":2020,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Organ Transplantation Techniques and Outcomes","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"","keywords":"Liver transplantation; Procurement; Medicine; Transplantation; Machine perfusion; Total cost; Perfusion; Marginal cost; Operations management; Surgery; Emergency medicine; Business; Internal medicine; Economics; Accounting","score_opus":0.01892164509931704,"score_gpt":0.3280509178730727,"score_spread":0.3091292727737557,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3103580978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9563981,0.006758946,0.0015758709,0.003494942,0.00009460392,0.000248004,0.0077482536,0.00005946003,0.02362177],"genre_scores_gemma":[0.99031854,0.00306161,0.0018721432,0.00019550513,0.000029663714,0.00004961733,0.0023420255,0.000015974287,0.0021149528],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99769115,0.0003487468,0.00009064928,0.00010760711,0.0010483295,0.0007135628],"domain_scores_gemma":[0.99747026,0.00035089502,0.0004954503,0.000042274343,0.0008973336,0.0007438231],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010535541,0.0006388388,0.00037626323,0.0021132212,0.001578858,0.0017484108,0.0011250317,0.00045233307,0.003947103],"category_scores_gemma":[0.00493713,0.0003169952,0.0011594412,0.0041410807,0.0006770364,0.0005379451,0.0010783734,0.0008374295,0.00022160288],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0032975588,0.00040821888,0.6575201,0.002298535,0.0013014149,0.0020992255,0.0011490412,0.06672924,0.0036859214,0.014939105,0.03079965,0.21577206],"study_design_scores_gemma":[0.00020673864,0.0004373286,0.9536985,0.0004981736,0.00051523536,0.0014787004,0.0020807309,0.021778908,0.001166511,0.0011357913,0.016824525,0.00017887949],"about_ca_topic_score_codex":0.97335464,"about_ca_topic_score_gemma":0.98072124,"teacher_disagreement_score":0.111574374,"about_ca_system_score_codex":0.111574374,"about_ca_system_score_gemma":0.07114677,"threshold_uncertainty_score":0.8095325},"labels":[],"label_agreement":null},{"id":"W3121637752","doi":"10.1007/s41669-021-00257-8","title":"The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Promotion and Cardiovascular Prevention","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Health Economics; University of Alberta","funders":"Alberta Innovates; Sanofi","keywords":"Medicine; Secondary prevention; Dyslipidemia; Health care; Disease; Disease burden; Cardiovascular event; Internal medicine; Emergency medicine; Pediatrics","score_opus":0.03160288090312003,"score_gpt":0.35144137744802484,"score_spread":0.3198384965449048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3121637752","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9665981,0.0047234134,0.00050495035,0.001762407,0.000070300914,0.00009371984,0.021955706,0.000024669514,0.0042667724],"genre_scores_gemma":[0.98870045,0.0009963383,0.0006990968,0.00022414885,0.000044826913,0.000041854222,0.008817124,0.0000027041817,0.00047361327],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9992968,0.00015526521,0.00009598014,0.00007061262,0.00025458305,0.00012672703],"domain_scores_gemma":[0.9990502,0.00009369913,0.00041673996,0.000025541322,0.00025577776,0.00015801907],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007062945,0.00033560934,0.00021928456,0.0012903356,0.00032431804,0.0008872498,0.0004956082,0.0003564845,0.0012606449],"category_scores_gemma":[0.0034638797,0.00016023505,0.0006606757,0.0020160596,0.00020053593,0.00046690504,0.0006710015,0.0005820495,0.00014420965],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000049116938,0.00003276571,0.99079776,0.00005254409,0.00023106084,0.00004935542,0.000050166946,0.00070773467,0.00002657576,0.00014682821,0.0025698317,0.005286179],"study_design_scores_gemma":[0.000016992812,0.00003876458,0.9953999,0.00009106181,0.00009809717,0.00015309773,0.00021571017,0.0018922598,0.000028498722,0.00012753667,0.0019298868,0.000008202279],"about_ca_topic_score_codex":0.37787107,"about_ca_topic_score_gemma":0.515881,"teacher_disagreement_score":0.37787107,"about_ca_system_score_codex":0.0037325125,"about_ca_system_score_gemma":0.0033531296,"threshold_uncertainty_score":0.75134325},"labels":[],"label_agreement":null},{"id":"W3125780982","doi":"10.1007/s41669-020-00244-5","title":"An Exploration on Attribute Non-attendance Using Discrete Choice Experiment Data from the Irish EQ-5D-5L National Valuation Study","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver Coastal Health Research Institute; Simon Fraser University; Vancouver Coastal Health","funders":"Health Research Board","keywords":"Valuation (finance); EQ-5D; Attendance; Irish; Latent class model; Discrete choice; Actuarial science; Quality-adjusted life year; Health care; Psychology; Econometrics; Medicine; Computer science; Health related quality of life; Economics; Machine learning; Cost effectiveness; Risk analysis (engineering); Disease","score_opus":0.8063207396074529,"score_gpt":0.5751746631831023,"score_spread":0.2311460764243506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3125780982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9607864,0.00028084728,0.031602252,0.000773279,0.000048986265,0.0013648345,0.00096741994,0.000023994951,0.00415198],"genre_scores_gemma":[0.9727966,0.00014886205,0.022006638,0.00041823278,0.000028718316,0.0027976541,0.0009772603,0.0000146456005,0.0008114631],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.89364916,0.098674,0.0018410739,0.001870971,0.003075832,0.00088884804],"domain_scores_gemma":[0.5171494,0.4516358,0.009947545,0.016841892,0.0038644362,0.00056090456],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.13012455,0.0005857445,0.000980876,0.0005560934,0.00071148324,0.0019643726,0.0013043067,0.0011093318,0.0034453163],"category_scores_gemma":[0.17815794,0.00033910468,0.0019998213,0.0011818238,0.0026446988,0.0022235878,0.0020719534,0.0026545739,0.0003279824],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024451029,0.021816317,0.5128828,0.0030031784,0.002479148,0.0008402481,0.039829627,0.040660795,0.003922221,0.1011476,0.0061736745,0.24279338],"study_design_scores_gemma":[0.00479721,0.033171378,0.51755553,0.0020585088,0.0023038404,0.00069753744,0.029248036,0.22469041,0.012038639,0.13883851,0.033674162,0.0009262804],"about_ca_topic_score_codex":0.0038730558,"about_ca_topic_score_gemma":0.0036037636,"teacher_disagreement_score":0.13012455,"about_ca_system_score_codex":0.0020837213,"about_ca_system_score_gemma":0.0019577434,"threshold_uncertainty_score":0.68817264},"labels":[],"label_agreement":null},{"id":"W3154274729","doi":"10.1007/s41669-021-00263-w","title":"Onwards and Upwards: A Systematic Survey of Economic Evaluation Methods in Oncology","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; Impact","funders":"","keywords":"Medicine; MEDLINE; Economic evaluation; Oncology; Family medicine; Internal medicine; Medical physics; Pathology","score_opus":0.670614332465464,"score_gpt":0.6442023617784887,"score_spread":0.026411970686975317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3154274729","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.009245648,0.9665246,0.006343194,0.00848858,0.0007107675,0.0031481069,0.0016392764,0.00005240569,0.0038475192],"genre_scores_gemma":[0.10547296,0.8493099,0.024498045,0.0083817355,0.0005504433,0.009885898,0.001238508,0.00013705889,0.00052531774],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.58366257,0.24520063,0.11782969,0.007139615,0.044271782,0.0018956535],"domain_scores_gemma":[0.27631843,0.6090941,0.061633408,0.00969538,0.041391734,0.0018670012],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.31267306,0.0018903546,0.007186534,0.025367709,0.0017130125,0.010385201,0.002307225,0.0027497632,0.004189628],"category_scores_gemma":[0.6413974,0.0021833323,0.009671258,0.024669426,0.0038088937,0.012670405,0.0064004757,0.0050402917,0.00045141284],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010830743,0.00009217023,0.010469771,0.5413224,0.00981506,0.00016330936,0.006228737,0.0006853434,0.0003110971,0.007030349,0.008781744,0.4140169],"study_design_scores_gemma":[0.00044918217,0.0004337229,0.011933359,0.9218006,0.008368604,0.0003818163,0.0029078636,0.0005219646,0.00028560148,0.0054840394,0.047304373,0.0001288208],"about_ca_topic_score_codex":0.0077626663,"about_ca_topic_score_gemma":0.013433329,"teacher_disagreement_score":0.6873269,"about_ca_system_score_codex":0.0134677505,"about_ca_system_score_gemma":0.028120415,"threshold_uncertainty_score":0.84759647},"labels":[],"label_agreement":null},{"id":"W3157834287","doi":"10.1007/s41669-021-00267-6","title":"Cost-effectiveness of a Province-wide Quality Improvement Initiative for Reducing Potentially Inappropriate Use of Antipsychotics in Long-Term Care in British Columbia, Canada","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Geriatric Care and Nursing Homes","field":"Health Professions","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Advancing Health Outcomes; BC Innovation Council; University of British Columbia; Brock University","funders":"Michael Smith Health Research BC","keywords":"Medicine; Quality-adjusted life year; Incremental cost-effectiveness ratio; Cost–utility analysis; Cohort; Baseline (sea); Cost effectiveness; Quality of life (healthcare); Cost–benefit analysis; Demography; Emergency medicine; Actuarial science; Pediatrics; Internal medicine","score_opus":0.10944140727985129,"score_gpt":0.4339944316592042,"score_spread":0.3245530243793529,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3157834287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9688525,0.0073993257,0.0020067727,0.0059187664,0.00017580394,0.0009462326,0.0075615654,0.0001545836,0.0069845337],"genre_scores_gemma":[0.99550617,0.0008824932,0.0012426825,0.00041162528,0.000017044651,0.00013922965,0.0012840811,0.0000067750584,0.0005097758],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.993836,0.002852546,0.00031759555,0.00045589596,0.0012086781,0.0013292672],"domain_scores_gemma":[0.9907651,0.0022309555,0.0013652353,0.00029197003,0.0028259493,0.0025207214],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052234917,0.0007873466,0.0009505919,0.0009821398,0.0011839732,0.0019412596,0.0018956745,0.0008894056,0.001894328],"category_scores_gemma":[0.016790299,0.00036681522,0.0020304392,0.0017757879,0.0007554736,0.00045971567,0.0016901643,0.0014793391,0.000092144284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01892405,0.0035430468,0.6068198,0.004551493,0.008747217,0.00043734454,0.00081271987,0.1494459,0.0010274472,0.004605019,0.027342828,0.17374311],"study_design_scores_gemma":[0.007039398,0.0042649508,0.8210622,0.002282546,0.0042035147,0.0002031592,0.0015309746,0.15171254,0.00040782773,0.0013182738,0.005792257,0.00018234464],"about_ca_topic_score_codex":0.9797688,"about_ca_topic_score_gemma":0.9847007,"teacher_disagreement_score":0.08438206,"about_ca_system_score_codex":0.08438206,"about_ca_system_score_gemma":0.09919485,"threshold_uncertainty_score":0.6122376},"labels":[],"label_agreement":null},{"id":"W3168701893","doi":"10.1007/s41669-021-00275-6","title":"Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Clinical Evaluative Sciences; Public Health Ontario; University of Toronto; University Health Network","funders":"Addis Ababa University","keywords":"Dolutegravir; Efavirenz; Human immunodeficiency virus (HIV); Medicine; Virology; Tenofovir; Second line; Pediatrics; Antiretroviral therapy; First line; Internal medicine; Viral load","score_opus":0.05826420296885351,"score_gpt":0.3741730334568439,"score_spread":0.31590883048799034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3168701893","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97825485,0.0053576822,0.009226256,0.0009943544,0.00006656964,0.00054898247,0.0016980901,0.000041681702,0.003811568],"genre_scores_gemma":[0.9962381,0.00064289785,0.002212603,0.00008683683,0.000009647653,0.00009313239,0.00025342,0.000005119058,0.00045822636],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9981091,0.0014441612,0.000054598047,0.00011186191,0.00010446115,0.0001757988],"domain_scores_gemma":[0.99354976,0.005442946,0.0004476095,0.00009220451,0.00022189658,0.00024572865],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0055822143,0.001098494,0.0015800776,0.0011734002,0.0002666385,0.0015312408,0.0010524797,0.0009598735,0.003368509],"category_scores_gemma":[0.009401938,0.00055423816,0.0030688783,0.0008408356,0.00045065567,0.0008348798,0.00095852464,0.0011072461,0.00011517232],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00401955,0.0004108834,0.0121766925,0.0005169823,0.0013261442,0.00036699203,0.000038919636,0.9697234,0.00048393727,0.0021708128,0.00042888036,0.008336671],"study_design_scores_gemma":[0.0014013685,0.0038442637,0.014453523,0.0004461913,0.0021741616,0.0004609181,0.00030273065,0.97222894,0.0012432488,0.0023878615,0.0009777243,0.00007901887],"about_ca_topic_score_codex":0.012989318,"about_ca_topic_score_gemma":0.0065455255,"teacher_disagreement_score":0.012989318,"about_ca_system_score_codex":0.006080299,"about_ca_system_score_gemma":0.0030911155,"threshold_uncertainty_score":0.04411584},"labels":[],"label_agreement":null},{"id":"W3177377347","doi":"10.1007/s41669-021-00279-2","title":"Non-Price-Related Determinants of Value and Access for Novel Non-small Cell Lung Cancer Treatments: A Cross-Country Review of HTA Decision Making","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Bristol-Myers Squibb","keywords":"Health technology; Agency (philosophy); Multivariate analysis; Actuarial science; Medicine; Business; Health care; Economics; Economic growth; Sociology; Internal medicine","score_opus":0.38378485757298003,"score_gpt":0.5879422646440101,"score_spread":0.20415740707103008,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3177377347","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02864833,0.9547487,0.0013788249,0.008213506,0.00038522296,0.00040912672,0.0020625142,0.000011309232,0.00414242],"genre_scores_gemma":[0.4009026,0.59011537,0.003808532,0.0025142496,0.00054629415,0.00054226693,0.0012391213,0.00003207376,0.00029951442],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9016776,0.056193348,0.022650585,0.003200873,0.014818886,0.0014586531],"domain_scores_gemma":[0.31980392,0.5687615,0.073945455,0.0051587,0.031060325,0.001270033],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.10791322,0.0005500438,0.0028367755,0.012064255,0.00061372045,0.007117448,0.0014864964,0.0013417829,0.0031013284],"category_scores_gemma":[0.3535994,0.00067233614,0.0058481884,0.020660447,0.0016893221,0.0032936824,0.0018034806,0.0019983859,0.0002467066],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019757564,0.00017060558,0.07335648,0.31004292,0.025414456,0.000539772,0.003889028,0.0037436958,0.00039871753,0.011883025,0.014606136,0.5539794],"study_design_scores_gemma":[0.00046527415,0.0010247543,0.19058177,0.6307476,0.047472086,0.0013333475,0.005623912,0.0029299688,0.0015822534,0.0085498085,0.10940429,0.00028489728],"about_ca_topic_score_codex":0.010939205,"about_ca_topic_score_gemma":0.016107634,"teacher_disagreement_score":0.10791322,"about_ca_system_score_codex":0.008761375,"about_ca_system_score_gemma":0.018217104,"threshold_uncertainty_score":0.5707065},"labels":[],"label_agreement":null},{"id":"W3185045240","doi":"10.1007/s41669-021-00286-3","title":"Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Nilotinib; Dasatinib; Medicine; Imatinib; Internal medicine; Tyrosine-kinase inhibitor; Myeloid leukemia; Tyrosine kinase; Cost effectiveness; Oncology; Cancer","score_opus":0.10076930907736435,"score_gpt":0.41178376477177653,"score_spread":0.31101445569441216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3185045240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.794802,0.0060648182,0.11125951,0.006071809,0.00036613713,0.0018459609,0.014301803,0.00030754512,0.06498038],"genre_scores_gemma":[0.9802239,0.0010495922,0.008394547,0.00031561,0.00004459352,0.0007293962,0.0021460466,0.000027830112,0.007068442],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99883753,0.0007600428,0.000028376167,0.000106658896,0.00007744186,0.00019008329],"domain_scores_gemma":[0.9979857,0.0015154398,0.00019994089,0.000032321022,0.0001350233,0.0001315064],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021983448,0.001908861,0.0015883559,0.0012626782,0.0004184465,0.001809795,0.002011652,0.0020903035,0.008063327],"category_scores_gemma":[0.004777253,0.00075045455,0.001981698,0.0011978197,0.0007284269,0.0009374102,0.0010131935,0.001638505,0.0004988565],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040345066,0.00006793598,0.0015648113,0.00008620077,0.00013923454,0.00013922817,0.000014375088,0.99197394,0.00010519321,0.0031231348,0.0005963294,0.0017860859],"study_design_scores_gemma":[0.0003908251,0.00035739763,0.0016253978,0.000055823893,0.00021453675,0.00012400861,0.00004984541,0.99363047,0.00008443702,0.002192898,0.0012571065,0.000017156204],"about_ca_topic_score_codex":0.024197536,"about_ca_topic_score_gemma":0.010520561,"teacher_disagreement_score":0.024197536,"about_ca_system_score_codex":0.0059288205,"about_ca_system_score_gemma":0.0039847866,"threshold_uncertainty_score":0.048113406},"labels":[],"label_agreement":null},{"id":"W3203942868","doi":"10.1007/s41669-021-00300-8","title":"Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Lipoproteins and Cardiovascular Health","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Amgen (Canada)","funders":"","keywords":"Evolocumab; Medicine; Ezetimibe; Familial hypercholesterolemia; Dyslipidemia; Statin; Internal medicine; Quality-adjusted life year; Alirocumab; Cost effectiveness; Cholesterol; Disease; Lipoprotein","score_opus":0.11329147644652462,"score_gpt":0.427569372084309,"score_spread":0.3142778956377844,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3203942868","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9762271,0.013626809,0.0031298709,0.0017994937,0.00008077098,0.00035864406,0.002040824,0.00003283713,0.0027038036],"genre_scores_gemma":[0.99713504,0.00124694,0.0008320912,0.00011459049,0.000010551251,0.000057897385,0.0004066803,0.0000029078933,0.00019333762],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9982685,0.0013403256,0.00007423397,0.00008363887,0.000121579586,0.00011162251],"domain_scores_gemma":[0.9944885,0.0039719753,0.0007001341,0.00010703147,0.00042752162,0.00030483914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004094328,0.0007510053,0.0009384767,0.0009998374,0.00015638505,0.00095899333,0.000622208,0.0007633923,0.0032509272],"category_scores_gemma":[0.012490645,0.00037830326,0.0023877942,0.0006814136,0.0002851455,0.00065866386,0.0007666675,0.00078508665,0.00011832412],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035846297,0.0011569215,0.07747707,0.0046890634,0.009855717,0.0010327619,0.00027414574,0.7813304,0.001982312,0.0068144873,0.0039824154,0.07555829],"study_design_scores_gemma":[0.010013983,0.012583775,0.08414384,0.0020844904,0.012767115,0.001320002,0.0009777793,0.8644638,0.001912387,0.004263435,0.0053083324,0.00016108436],"about_ca_topic_score_codex":0.029617358,"about_ca_topic_score_gemma":0.016322242,"teacher_disagreement_score":0.029617358,"about_ca_system_score_codex":0.00564916,"about_ca_system_score_gemma":0.0030292273,"threshold_uncertainty_score":0.058889925},"labels":[],"label_agreement":null},{"id":"W3205515305","doi":"10.1007/s41669-021-00304-4","title":"Budget Impact Analysis of an Epigenetic Test Used for Diagnosing Fetal Alcohol Spectrum Disorder from the Perspective of a Laboratory Budget Holder in Manitoba, Canada","year":2021,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Prenatal Substance Exposure Effects","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hospital for Sick Children; University of Toronto; SickKids Foundation; University of Manitoba; Institute for Clinical Evaluative Sciences; University of Calgary","funders":"Kids Brain Health Network; Canada Research Chairs","keywords":"Fetal Alcohol Spectrum Disorder; Prenatal alcohol exposure; Population; Medicine; DNA methylation; Fetal alcohol syndrome; Environmental health; Demography; Biology; Genetics; Pregnancy","score_opus":0.020683420006045512,"score_gpt":0.3300818351518783,"score_spread":0.3093984151458328,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205515305","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9202475,0.0034239972,0.01837786,0.00828171,0.00011720487,0.0017013873,0.01971083,0.00015873357,0.027980814],"genre_scores_gemma":[0.99108785,0.0008383787,0.003499817,0.00033890072,0.0000126731275,0.00016998796,0.0019971333,0.0000126318355,0.0020427455],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9949964,0.0022116478,0.00015816165,0.0004761218,0.0007944556,0.0013631597],"domain_scores_gemma":[0.987852,0.0072072283,0.0011517957,0.0002541921,0.0025203351,0.0010143825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007912557,0.0010851445,0.0009333449,0.0020979973,0.0013937877,0.00276197,0.0024279428,0.0011709298,0.0040466934],"category_scores_gemma":[0.018292729,0.0009845753,0.002256972,0.0024923815,0.0012183998,0.00093366735,0.0017638064,0.0019117875,0.00019070422],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00070627284,0.00017657563,0.075205505,0.00023141691,0.00058643415,0.0005435428,0.00017982488,0.8994252,0.00030032286,0.007927114,0.0035056379,0.011212084],"study_design_scores_gemma":[0.00036263154,0.0006262766,0.08505545,0.00036522033,0.0009226711,0.00027256762,0.0015502919,0.8992144,0.00056506036,0.0039982805,0.0069011915,0.00016605777],"about_ca_topic_score_codex":0.9617535,"about_ca_topic_score_gemma":0.920301,"teacher_disagreement_score":0.103758864,"about_ca_system_score_codex":0.103758864,"about_ca_system_score_gemma":0.06309205,"threshold_uncertainty_score":0.7528268},"labels":[],"label_agreement":null},{"id":"W3210263997","doi":"10.1007/s41669-021-00309-z","title":"Community Distribution of Naloxone: A Systematic Review of Economic Evaluations","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Opioid Use Disorder Treatment","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Impact","funders":"","keywords":"(+)-Naloxone; EconLit; Medicine; Quality (philosophy); Economic evaluation; MEDLINE; Actuarial science; Business; Opioid; Political science","score_opus":0.11850715075104147,"score_gpt":0.49336442256005686,"score_spread":0.3748572718090154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3210263997","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016292258,0.9949315,0.00045835244,0.0006088114,0.0001783095,0.0012647148,0.0004385884,0.000013395332,0.0004770845],"genre_scores_gemma":[0.040231712,0.95247775,0.0025192874,0.00078757136,0.0001466434,0.0033088261,0.00036383586,0.000016969267,0.00014739703],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.94163316,0.031905,0.01498851,0.0016800837,0.008794547,0.0009986324],"domain_scores_gemma":[0.8069835,0.15695696,0.020576509,0.0021516918,0.012400483,0.0009308504],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04974859,0.0026768441,0.01498777,0.019108532,0.0011257081,0.0054505747,0.0030041959,0.0031815702,0.005308699],"category_scores_gemma":[0.19127844,0.0018222764,0.01406407,0.015969025,0.0016379973,0.0041542333,0.002571921,0.003021235,0.00030664832],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00071677245,0.00003654244,0.0005252583,0.944087,0.018593859,0.000098326156,0.00013350502,0.00026160464,0.00007018401,0.00043622212,0.0010635406,0.03397725],"study_design_scores_gemma":[0.00089193793,0.00038906935,0.0024483434,0.8865234,0.09871799,0.0002247459,0.0002964183,0.00030510314,0.00019700818,0.00078363426,0.009169642,0.000052692234],"about_ca_topic_score_codex":0.0077586155,"about_ca_topic_score_gemma":0.019398235,"teacher_disagreement_score":0.04974859,"about_ca_system_score_codex":0.012897426,"about_ca_system_score_gemma":0.01963923,"threshold_uncertainty_score":0.26309884},"labels":[],"label_agreement":null},{"id":"W3215778396","doi":"10.1007/s41669-021-00311-5","title":"Similarities and Differences in Health Technology Assessment Systems and Implications for Coverage Decisions: Evidence from 32 Countries","year":2021,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":86,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Consumers, Health, Agriculture and Food Executive Agency; Directorate-General for Health and Consumers","keywords":"Health technology; Transparency (behavior); Scope (computer science); Negotiation; European union; Transformative learning; Business; Political science; Public economics; Process management; Medicine; Health care; Psychology; Computer science; Economics","score_opus":0.6845194897058882,"score_gpt":0.5941363569088085,"score_spread":0.09038313279707966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3215778396","genre_codex":"empirical","genre_gemma":"review","domain_codex":null,"domain_gemma":"evaluation","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":null,"domain_candidate":"evaluation","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.52503675,0.41459078,0.0077655762,0.009525818,0.00024920574,0.0014590321,0.0056376094,0.00005351501,0.035681736],"genre_scores_gemma":[0.94142544,0.050506514,0.0044206246,0.0014940754,0.00003952038,0.00061135314,0.0012895103,0.000031534037,0.00018143834],"study_design_codex":"observational","study_design_gemma":"systematic_review","domain_scores_codex":[0.86144495,0.079363294,0.03333124,0.006646003,0.016133802,0.0030807497],"domain_scores_gemma":[0.5494497,0.34787005,0.06987765,0.010187358,0.02072913,0.001886114],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.07801989,0.00040262798,0.0017976176,0.015035819,0.0012289486,0.0067193666,0.001615638,0.0013670953,0.0028404372],"category_scores_gemma":[0.31058824,0.0009840961,0.0033324934,0.02897089,0.0029947204,0.005004801,0.0059358473,0.0016966099,0.00023131847],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015827573,0.00017799804,0.47375596,0.06328865,0.005671776,0.0008862729,0.027562512,0.00410507,0.00031482364,0.020555602,0.0048296833,0.39726895],"study_design_scores_gemma":[0.00047668992,0.00049259735,0.7903033,0.12212119,0.007236778,0.0014353725,0.022204613,0.0014020072,0.00091502635,0.0064642644,0.04675552,0.00019259105],"about_ca_topic_score_codex":0.029130911,"about_ca_topic_score_gemma":0.024346335,"teacher_disagreement_score":0.92198014,"about_ca_system_score_codex":0.009086553,"about_ca_system_score_gemma":0.011192719,"threshold_uncertainty_score":0.4126135},"labels":[],"label_agreement":null},{"id":"W4206796574","doi":"10.1007/s41669-021-00321-3","title":"Prevalence and Cost of Care for Parkinson’s Disease in Luxembourg: An Analysis of National Healthcare Insurance Data","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Fonds National de la Recherche Luxembourg","keywords":"Health care; Disease; National health insurance; Work (physics); Health insurance; National Insurance; Health data; Health economics","score_opus":0.07838141638964154,"score_gpt":0.410851852721078,"score_spread":0.33247043633143647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206796574","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97967726,0.0028360982,0.00022987014,0.0004688841,0.000022744212,0.00005407123,0.015772656,0.000019008414,0.0009193727],"genre_scores_gemma":[0.9833756,0.0010174713,0.0004425107,0.00011691533,0.000028432543,0.00012061122,0.014706814,0.00000677899,0.00018483642],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99844944,0.00052688824,0.00028432434,0.00019677749,0.00033131882,0.0002111372],"domain_scores_gemma":[0.99681073,0.0007059388,0.0016386542,0.00011781039,0.0005187668,0.0002080331],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002071851,0.0004182461,0.0005295764,0.005240067,0.00023142257,0.00074166845,0.0005431685,0.00033046005,0.0017392443],"category_scores_gemma":[0.0051745037,0.00021433749,0.0013248224,0.0060424674,0.00031218037,0.00068219693,0.0008857909,0.00041677846,0.00022811614],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009535733,0.000019517216,0.9928767,0.00017767468,0.00034248148,0.00009904931,0.00018029562,0.0002896737,0.000037412152,0.00010245453,0.0015834499,0.004195993],"study_design_scores_gemma":[0.000014289997,0.000034831013,0.99824667,0.0000724793,0.00006588078,0.00011018329,0.00022078992,0.00043593944,0.000016413323,0.00002794771,0.0007483961,0.0000061853475],"about_ca_topic_score_codex":0.07331832,"about_ca_topic_score_gemma":0.0466372,"teacher_disagreement_score":0.07331832,"about_ca_system_score_codex":0.0037530935,"about_ca_system_score_gemma":0.0011661402,"threshold_uncertainty_score":0.14578307},"labels":[],"label_agreement":null},{"id":"W4224952615","doi":"10.1007/s41669-022-00330-w","title":"Medical and Non-medical Costs of Sickle Cell Disease and Treatments from a US Perspective: A Systematic Review and Landscape Analysis","year":2022,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"National Heart, Lung, and Blood Institute; National Institutes of Health","keywords":"Disease; Perspective (graphical); Medicine; Intensive care medicine; Medical costs; Health care; Pathology; Computer science; Political science","score_opus":0.018449751082903452,"score_gpt":0.36386667155065927,"score_spread":0.3454169204677558,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4224952615","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0049722777,0.99008054,0.00022299892,0.0005969275,0.000059221296,0.00025057048,0.00324507,0.00001068885,0.0005616494],"genre_scores_gemma":[0.076142885,0.91958755,0.0010384304,0.0006699242,0.00009771421,0.0007962879,0.0014989978,0.000013197095,0.00015496807],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.98735064,0.0039763106,0.005199457,0.0008192053,0.0022402962,0.00041401733],"domain_scores_gemma":[0.95086145,0.034411103,0.010324898,0.0004456493,0.0035657436,0.00039121546],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009145549,0.0014343993,0.009219975,0.02599552,0.00057134347,0.0032171477,0.0017150497,0.0017096153,0.0041662105],"category_scores_gemma":[0.047748648,0.00095536,0.01333987,0.030646676,0.00063616905,0.0025666212,0.0017867185,0.0013053667,0.00023510352],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00049057085,0.000025649762,0.008312591,0.89317465,0.055207603,0.00024789872,0.00022102508,0.00055241224,0.00011989989,0.000704191,0.0029114343,0.03803198],"study_design_scores_gemma":[0.00049480627,0.00028797923,0.031551726,0.6616667,0.2831134,0.0010892077,0.00059943943,0.00074476335,0.00019274419,0.0012382183,0.018931253,0.000089825364],"about_ca_topic_score_codex":0.014546922,"about_ca_topic_score_gemma":0.033792812,"teacher_disagreement_score":0.02599552,"about_ca_system_score_codex":0.0057369308,"about_ca_system_score_gemma":0.0077283895,"threshold_uncertainty_score":0.048366845},"labels":[],"label_agreement":null},{"id":"W4225004644","doi":"10.1007/s41669-022-00331-9","title":"Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Population Health Research Institute; Takeda (Canada)","funders":"","keywords":"Vedolizumab; Medicine; Tofacitinib; Golimumab; Ustekinumab; Ulcerative colitis; Infliximab; Adalimumab; Internal medicine; Disease","score_opus":0.023059148200213,"score_gpt":0.31087088664332546,"score_spread":0.2878117384431125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225004644","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97632056,0.0050091366,0.00204913,0.0029622293,0.00003057141,0.00030194258,0.004364277,0.000062348365,0.008899805],"genre_scores_gemma":[0.9971486,0.0007965635,0.00074515596,0.000100662175,0.0000051871207,0.000024391724,0.0006942939,0.0000050314293,0.00047996157],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99875104,0.00037472148,0.000049226364,0.0000978465,0.00035903306,0.0003681061],"domain_scores_gemma":[0.99722433,0.001046277,0.0004721786,0.00005310966,0.0006736233,0.00053050864],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0017010657,0.0004280601,0.0005426477,0.00086742453,0.00083909126,0.0014621253,0.0011037434,0.000516906,0.0023308652],"category_scores_gemma":[0.0070091933,0.00034946195,0.001159708,0.0012532169,0.00052501756,0.000424339,0.0006929084,0.000825004,0.00007328922],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009610333,0.00081529364,0.34986708,0.00093357265,0.0020884,0.0008016233,0.00039755803,0.5068153,0.0014553939,0.011151696,0.009134454,0.10692924],"study_design_scores_gemma":[0.0015136814,0.0014047262,0.20693496,0.00040952658,0.0015931111,0.0004012764,0.00086685206,0.77804196,0.00085528434,0.002646566,0.0052081654,0.00012384045],"about_ca_topic_score_codex":0.97219795,"about_ca_topic_score_gemma":0.9654682,"teacher_disagreement_score":0.06317417,"about_ca_system_score_codex":0.06317417,"about_ca_system_score_gemma":0.05149329,"threshold_uncertainty_score":0.45836288},"labels":[],"label_agreement":null},{"id":"W4285391949","doi":"10.1007/s41669-022-00347-1","title":"Using Health Economics to Inform Immunization Policy Across All Levels of Government","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Vaccine Coverage and Hesitancy","field":"Social Sciences","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta","funders":"Canadian Institutes of Health Research","keywords":"Government (linguistics); Scope (computer science); Immunization; Work (physics); Process (computing); Health care; Business; Public relations; Political science; Economic growth; Medicine; Economics; Computer science","score_opus":0.15821961852435548,"score_gpt":0.47921207765072615,"score_spread":0.32099245912637064,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285391949","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.087616935,0.01806422,0.16060013,0.4740852,0.00085099274,0.0020627056,0.001953154,0.00035143297,0.25441533],"genre_scores_gemma":[0.86081696,0.013354098,0.10814359,0.011468858,0.00039651533,0.0007528357,0.00048802976,0.00008586399,0.004493264],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"not_applicable","domain_scores_codex":[0.9479716,0.04212246,0.0022767745,0.0011598993,0.0043486357,0.0021206618],"domain_scores_gemma":[0.87071127,0.106056,0.006503271,0.0036607126,0.010942014,0.0021266816],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.08472916,0.00096963695,0.0016295345,0.011026235,0.0037616824,0.01806292,0.0020950064,0.0027048138,0.0073262006],"category_scores_gemma":[0.1577145,0.000835534,0.0011432236,0.0058607887,0.005466941,0.014223916,0.0057024756,0.0052386923,0.0005849426],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00013804476,0.0002590934,0.047019783,0.0014222027,0.0005791786,0.00043099347,0.0069168336,0.05128022,0.00038709148,0.64300585,0.037543584,0.21101713],"study_design_scores_gemma":[0.00008987961,0.000083955536,0.02191056,0.004124469,0.0002139927,0.0000803079,0.014656558,0.031311084,0.0008033858,0.8152102,0.111351036,0.00016450178],"about_ca_topic_score_codex":0.14636248,"about_ca_topic_score_gemma":0.18087994,"teacher_disagreement_score":0.14636248,"about_ca_system_score_codex":0.035867963,"about_ca_system_score_gemma":0.065118216,"threshold_uncertainty_score":0.44809598},"labels":[],"label_agreement":null},{"id":"W4286494041","doi":"10.1007/s41669-022-00355-1","title":"Cost-Utility Analysis of Planned Early Delivery or Expectant Management for Late Preterm Pre-eclampsia (PHOENIX)","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Pregnancy and preeclampsia studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Oxford University Hospitals NHS Foundation Trust; Dalhousie University; University of Oxford; Health Technology Assessment Programme; Imperial College London; University of Bristol; National Institute for Health and Care Research; University Hospital Southampton NHS Foundation Trust","keywords":"Medicine; Obstetrics; Confidence interval; Gestation; Pregnancy; Pediatrics","score_opus":0.077040696318964,"score_gpt":0.366985040062162,"score_spread":0.289944343743198,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4286494041","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9790339,0.012819705,0.0026237443,0.00090284727,0.000114795585,0.0009882431,0.0017226319,0.000030013689,0.0017640776],"genre_scores_gemma":[0.99637765,0.0012013639,0.0011389557,0.000116488656,0.000020977468,0.00036161707,0.0004210786,0.000003863743,0.00035795418],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9955996,0.0037242025,0.0001207627,0.00023170158,0.00018169858,0.00014193828],"domain_scores_gemma":[0.99633235,0.0027765965,0.00051759445,0.00008377198,0.00008706696,0.00020264807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005618446,0.0008395451,0.001730695,0.00057670684,0.000094484145,0.0010493641,0.00069939584,0.000893495,0.0053980807],"category_scores_gemma":[0.011747567,0.0002997678,0.0035990258,0.00053668726,0.00035669457,0.0005984632,0.0008037327,0.0011822118,0.00013618014],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.61356616,0.0034439375,0.054328963,0.012534462,0.03668935,0.0004560551,0.00025725446,0.13219123,0.002375932,0.0034550717,0.0029068869,0.13779472],"study_design_scores_gemma":[0.23453489,0.24317217,0.19332176,0.004087939,0.06620228,0.001073823,0.0007449917,0.2411168,0.0033459999,0.007157344,0.0049786395,0.00026341502],"about_ca_topic_score_codex":0.0031222263,"about_ca_topic_score_gemma":0.0022540928,"teacher_disagreement_score":0.005618446,"about_ca_system_score_codex":0.0022048738,"about_ca_system_score_gemma":0.0009151319,"threshold_uncertainty_score":0.029713571},"labels":[],"label_agreement":null},{"id":"W4295905156","doi":"10.1007/s41669-022-00363-1","title":"Cost-Effectiveness Analysis of Ofatumumab for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Novartis (Canada); EVERSANA (Canada); Memorial University of Newfoundland; University of British Columbia; Queen's University","funders":"Novartis Pharmaceuticals Canada","keywords":"Relapsing remitting; Ofatumumab; Multiple sclerosis; Medicine; Physical medicine and rehabilitation; Internal medicine; Psychiatry","score_opus":0.22839817792887346,"score_gpt":0.41324001322696846,"score_spread":0.184841835298095,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4295905156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9164658,0.021327702,0.0050019724,0.0076640206,0.0002499217,0.0017734318,0.02652692,0.00017787934,0.020812275],"genre_scores_gemma":[0.98774683,0.0036227794,0.0025075695,0.00037970275,0.000027507738,0.00018877481,0.0038616324,0.000019591853,0.0016455161],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9983557,0.0005978613,0.000074144584,0.00015273562,0.00043643318,0.00038313458],"domain_scores_gemma":[0.99603564,0.0014426069,0.00039811677,0.00008918872,0.0014832714,0.0005511807],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0025533268,0.00093216647,0.0013077367,0.0020665918,0.0010576134,0.0017574857,0.0017439282,0.0008956797,0.0038972911],"category_scores_gemma":[0.010742792,0.0005585462,0.0026681267,0.0028941722,0.0005612003,0.0005099096,0.00081038574,0.0011999672,0.00014620778],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01163288,0.00086898304,0.13556963,0.0034157645,0.007935837,0.0009368504,0.00030214386,0.7266483,0.00090112694,0.018682627,0.024076113,0.069029726],"study_design_scores_gemma":[0.0060737706,0.0014111109,0.11783327,0.0011698842,0.007927898,0.00046633143,0.0008057254,0.8449687,0.00069279055,0.005480406,0.012906977,0.0002631518],"about_ca_topic_score_codex":0.9800939,"about_ca_topic_score_gemma":0.9712625,"teacher_disagreement_score":0.08088894,"about_ca_system_score_codex":0.08088894,"about_ca_system_score_gemma":0.09494025,"threshold_uncertainty_score":0.5868931},"labels":[],"label_agreement":null},{"id":"W4308254443","doi":"10.1007/s41669-022-00375-x","title":"A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada","year":2022,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"ABB (Canada); Foothills Medical Centre","funders":"AbbVie","keywords":"Obinutuzumab; Venetoclax; Medicine; Chlorambucil; Rituximab; Bendamustine; Internal medicine; Fludarabine; Chronic lymphocytic leukemia; Ibrutinib; Oncology; Population; Ofatumumab; Cyclophosphamide; Leukemia; Chemotherapy; Lymphoma","score_opus":0.04922340262774139,"score_gpt":0.3689317120683685,"score_spread":0.3197083094406271,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308254443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93605983,0.00634884,0.0125950575,0.004386454,0.0000941679,0.0015870587,0.016394459,0.00012921108,0.022404872],"genre_scores_gemma":[0.9917318,0.0010730946,0.002328823,0.00020356562,0.000017565306,0.00024958514,0.0019128402,0.000012267543,0.0024704146],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.9977672,0.00111215,0.00005525137,0.00020680168,0.00024426408,0.00061419164],"domain_scores_gemma":[0.99165267,0.0058138734,0.0006572704,0.00015222219,0.0010310597,0.0006928768],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0046508857,0.0016020308,0.0018592956,0.0016368048,0.0010229704,0.0025015005,0.002788812,0.0018648934,0.004978959],"category_scores_gemma":[0.012788393,0.0010529642,0.0028573382,0.0020238014,0.0012130309,0.0008750095,0.0012603777,0.0020208096,0.00017719383],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010976673,0.000112011294,0.0040231496,0.00015974707,0.0002891443,0.00016436199,0.000040675965,0.9851151,0.00012676115,0.0045562657,0.0011153126,0.003199698],"study_design_scores_gemma":[0.0007796027,0.0005722719,0.007774225,0.00013366116,0.0007296178,0.00010763601,0.00020390947,0.98458266,0.00017920947,0.0027528096,0.0021188788,0.00006544513],"about_ca_topic_score_codex":0.8094695,"about_ca_topic_score_gemma":0.60551405,"teacher_disagreement_score":0.19053048,"about_ca_system_score_codex":0.044344883,"about_ca_system_score_gemma":0.024275735,"threshold_uncertainty_score":0.38330507},"labels":[],"label_agreement":null},{"id":"W4321490951","doi":"10.1007/s41669-023-00396-0","title":"Evaluation of Cost-Effectiveness of Adjuvant Osimertinib in Patients with Resected EGFR Mutation-Positive Non-small Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"AstraZeneca (Canada); Princess Margaret Cancer Centre; University of Toronto; University Health Network; Hôpital Charles-Le Moyne; William Osler Health System","funders":"AstraZeneca","keywords":"Osimertinib; Medicine; Adjuvant; Lung cancer; Oncology; Internal medicine; Quality of life (healthcare); Disease; Cost effectiveness; Quality-adjusted life year; Cancer; Epidermal growth factor receptor","score_opus":0.040697525512166634,"score_gpt":0.4178555083762873,"score_spread":0.37715798286412067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4321490951","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883736,0.0029566167,0.0031385152,0.00078625954,0.00003584953,0.00043044143,0.001986684,0.000029701832,0.002262448],"genre_scores_gemma":[0.99783796,0.0003912927,0.00074478454,0.000053137832,0.0000052219425,0.00006959735,0.0007009657,0.0000022136708,0.00019481569],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.999255,0.00044703184,0.000036120135,0.00007995868,0.00007496945,0.000107024396],"domain_scores_gemma":[0.99785185,0.0015383431,0.00019829135,0.00005916627,0.00014186362,0.00021045754],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0028381825,0.00070782745,0.0011566111,0.00038253577,0.00021687963,0.00095112505,0.00091731787,0.0006114851,0.0017241209],"category_scores_gemma":[0.008120291,0.0003244513,0.0021386102,0.00054625486,0.000332078,0.0005293049,0.0004710412,0.00083921204,0.00009082145],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03219798,0.0015592834,0.058276594,0.0008592337,0.00234275,0.00035086786,0.00010735563,0.8550817,0.0011256435,0.0029855398,0.0013882169,0.043724824],"study_design_scores_gemma":[0.0047548385,0.012631075,0.04542714,0.00024132094,0.0033382503,0.00021230492,0.00019628782,0.9280766,0.0011510276,0.0020703326,0.0018373961,0.00006336771],"about_ca_topic_score_codex":0.11138311,"about_ca_topic_score_gemma":0.08333187,"teacher_disagreement_score":0.11138311,"about_ca_system_score_codex":0.0076630493,"about_ca_system_score_gemma":0.005432114,"threshold_uncertainty_score":0.22146958},"labels":[],"label_agreement":null},{"id":"W4323921312","doi":"10.1007/s41669-023-00400-7","title":"Cost Analysis of a Transition Care Bundle Compared with Usual Care for COPD Patients Being Discharged from Hospital: Evaluation of a Randomized Controlled Trial","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Health Services; University of Calgary; Alberta Health; University of Alberta; Institute of Health Economics","funders":"University of Alberta; Canadian Institutes of Health Research; Alberta Innovates - Health Solutions; Alberta Health Services","keywords":"Randomized controlled trial; Medicine; COPD; Bundle; Emergency medicine; Internal medicine","score_opus":0.044061459394029855,"score_gpt":0.3905816534093894,"score_spread":0.34652019401535955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323921312","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96913505,0.009762931,0.0019712225,0.0014538604,0.0017680111,0.012341566,0.0014844727,0.00025091867,0.0018319344],"genre_scores_gemma":[0.97936773,0.0028380796,0.0030065777,0.00084663444,0.00059467764,0.011284133,0.0008359944,0.000024971549,0.0012011421],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9922193,0.0055074366,0.0005163724,0.00065284147,0.0005244595,0.0005795768],"domain_scores_gemma":[0.9920719,0.0038812242,0.0017749874,0.00041072926,0.00065329287,0.0012078014],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0066226255,0.0025112687,0.0061448882,0.0009981185,0.00072411227,0.0018649003,0.0020931151,0.0032439046,0.0065962994],"category_scores_gemma":[0.013673405,0.00090851524,0.00779283,0.0010020541,0.0015895716,0.0016684813,0.001098359,0.004094666,0.00039915848],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9870837,0.002641982,0.0005598874,0.000914775,0.0026713675,0.000018867297,0.000027664266,0.00043399833,0.000090114605,0.00008085936,0.00025009832,0.0052267285],"study_design_scores_gemma":[0.96197766,0.0312031,0.0016933064,0.00018224266,0.0026786865,0.000013377257,0.00003134374,0.001756552,0.00006694277,0.00019387867,0.00018465308,0.000018247318],"about_ca_topic_score_codex":0.014753192,"about_ca_topic_score_gemma":0.011437916,"teacher_disagreement_score":0.014753192,"about_ca_system_score_codex":0.005303746,"about_ca_system_score_gemma":0.004064635,"threshold_uncertainty_score":0.038481534},"labels":[],"label_agreement":null},{"id":"W4360601194","doi":"10.1007/s41669-023-00406-1","title":"Healthcare Payer Perspectives on the Assessment and Pricing of Oncology Multi-Indication Products: Evidence from Nine OECD Countries","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Novartis","keywords":"Purchasing; Discounting; Health care; Thematic analysis; Value-Based Purchasing; Business; Reimbursement; Actuarial science; Public economics; Marketing; Economics; Qualitative research; Economic growth; Finance","score_opus":0.5573958734861583,"score_gpt":0.5653476281504209,"score_spread":0.007951754664262678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360601194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8076895,0.12634718,0.0007221541,0.016391886,0.00028864725,0.00022829042,0.0018546204,0.000020115716,0.046457607],"genre_scores_gemma":[0.96050996,0.03578278,0.0005040627,0.0023621002,0.00006554044,0.000072250456,0.00042234873,0.000011182106,0.00026981818],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97101,0.017303215,0.0039194804,0.0008449537,0.005341405,0.0015808766],"domain_scores_gemma":[0.8231201,0.120444,0.03435641,0.0029663125,0.016756825,0.002356327],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.042426713,0.00030268845,0.0005754678,0.004010366,0.0008937901,0.005677338,0.0009802935,0.0009814505,0.003095047],"category_scores_gemma":[0.091285005,0.00025932136,0.0011430292,0.008053069,0.002403597,0.0026665155,0.0033189182,0.0012245062,0.00016810912],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017203998,0.00029791798,0.6314698,0.017928671,0.0010626499,0.001915921,0.049880266,0.0010543793,0.00022279068,0.012160117,0.0113880895,0.2708991],"study_design_scores_gemma":[0.00019662012,0.00047071045,0.7592067,0.033792477,0.0012434545,0.0012300765,0.12430989,0.00052488194,0.00056129985,0.0013768763,0.07696295,0.00012398807],"about_ca_topic_score_codex":0.041269127,"about_ca_topic_score_gemma":0.025888804,"teacher_disagreement_score":0.042426713,"about_ca_system_score_codex":0.009149573,"about_ca_system_score_gemma":0.008863912,"threshold_uncertainty_score":0.22437662},"labels":[],"label_agreement":null},{"id":"W4364376102","doi":"10.1007/s41669-023-00409-y","title":"Economic Evaluation Comparing Virtual Reality with Child Life Programming for Non-sedated Pediatric Medical Imaging: A Cost-Consequence Analysis","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Pediatric Pain Management Techniques","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; BC Children's Hospital; University of British Columbia","funders":"Mitacs","keywords":"Virtual reality; Psychology; Computer science; Human–computer interaction","score_opus":0.06749193653518161,"score_gpt":0.4162319603709268,"score_spread":0.3487400238357452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4364376102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8847894,0.036738653,0.027593229,0.0032207477,0.00033413098,0.012294232,0.009479666,0.00009065569,0.025459217],"genre_scores_gemma":[0.9822886,0.0048235273,0.008667054,0.0002973465,0.000043742697,0.0017466035,0.0012911045,0.000012337099,0.0008296398],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.98073673,0.0151543,0.000776439,0.0004442691,0.0021427416,0.0007454859],"domain_scores_gemma":[0.9736395,0.020982273,0.002190165,0.0003963251,0.002153421,0.0006383538],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015233758,0.0013068229,0.0021516657,0.002705147,0.00038772315,0.0025385222,0.0010016833,0.0009124559,0.00450293],"category_scores_gemma":[0.042716786,0.0004779249,0.0051016016,0.0029809405,0.00070058496,0.0010762315,0.001005324,0.0014533561,0.0001322678],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07778125,0.004603371,0.08851868,0.019591983,0.029751113,0.0010825926,0.00040481202,0.5204093,0.0018435958,0.02446372,0.0072733425,0.22427627],"study_design_scores_gemma":[0.027326528,0.053932898,0.15763444,0.010217397,0.055589423,0.0020694125,0.0024849346,0.64313453,0.0048594396,0.020079087,0.022109078,0.0005628582],"about_ca_topic_score_codex":0.027313458,"about_ca_topic_score_gemma":0.017286068,"teacher_disagreement_score":0.027313458,"about_ca_system_score_codex":0.013396058,"about_ca_system_score_gemma":0.00910287,"threshold_uncertainty_score":0.097195625},"labels":[],"label_agreement":null},{"id":"W4366351945","doi":"10.1007/s41669-023-00407-0","title":"Healthcare Resource Utilization and Costs in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer Receiving First-Line Treatment in the United States: An Insurance Claims-Based Descriptive Analysis","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Osimertinib; Medicine; Lung cancer; Health care; Population; Oncology; Disease; Internal medicine; Chemotherapy; Cancer; Intensive care medicine; Epidermal growth factor receptor; Erlotinib; Environmental health","score_opus":0.041307286050652516,"score_gpt":0.38080286673296865,"score_spread":0.3394955806823161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4366351945","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98378927,0.00040418832,0.00008355091,0.00012318103,0.000005986587,0.00004326664,0.014932908,0.000008046727,0.0006096008],"genre_scores_gemma":[0.9883464,0.00029667,0.0001527986,0.00007568199,0.000012300724,0.000078295496,0.010903405,0.00000336794,0.00013112153],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99907696,0.00018049737,0.00026092306,0.00015818013,0.00020338623,0.00012000291],"domain_scores_gemma":[0.99594694,0.0008147579,0.002498498,0.00013259011,0.0003274078,0.00027976005],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009285215,0.00028764334,0.00044727983,0.00305554,0.00034429197,0.0008970346,0.00063616846,0.00045607347,0.0014050197],"category_scores_gemma":[0.0036553356,0.00027804554,0.0011236623,0.00455388,0.0002575058,0.0008456498,0.00080991175,0.0006792626,0.00021812931],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009318892,0.000055005647,0.9979063,0.000031227155,0.00013867588,0.00003688269,0.00006013798,0.00024223013,0.00002551972,0.000045322722,0.00056342885,0.0008019931],"study_design_scores_gemma":[0.000014834219,0.000077307406,0.9973145,0.000030934803,0.000055124743,0.00019232793,0.00046609505,0.0013381083,0.000034733137,0.000048749218,0.00041809888,0.000009071402],"about_ca_topic_score_codex":0.02802157,"about_ca_topic_score_gemma":0.023296524,"teacher_disagreement_score":0.02802157,"about_ca_system_score_codex":0.0013093656,"about_ca_system_score_gemma":0.0008700424,"threshold_uncertainty_score":0.05571693},"labels":[],"label_agreement":null},{"id":"W4367175132","doi":"10.1007/s41669-023-00415-0","title":"Humanistic and Economic Burden of IgA Nephropathy: Systematic Literature Reviews and Narrative Synthesis","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Renal Diseases and Glomerulopathies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Systematic review; Medicine; Critical appraisal; Checklist; Grey literature; MEDLINE; Nephropathy; Quality of life (healthcare); Economic evaluation; Health care; Family medicine; Intensive care medicine; Alternative medicine; Psychology; Nursing; Pathology; Political science","score_opus":0.08089463607554481,"score_gpt":0.4101879574652315,"score_spread":0.3292933213896867,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4367175132","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021450568,0.9853768,0.0016603004,0.0037614799,0.00079181686,0.0026186788,0.0022028345,0.000029282142,0.0014137784],"genre_scores_gemma":[0.06481368,0.9113717,0.007725528,0.0046373927,0.0008020108,0.009079895,0.0011748923,0.000030508609,0.00036438278],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.89288956,0.059176788,0.029294299,0.0032884441,0.013712368,0.0016386125],"domain_scores_gemma":[0.72698534,0.21620591,0.036702596,0.003780268,0.015081225,0.0012447129],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.08765125,0.0029087644,0.010152331,0.025649093,0.0011843346,0.008719265,0.0027439767,0.0033083088,0.007128742],"category_scores_gemma":[0.2885719,0.0018033818,0.011024473,0.016802505,0.0024662497,0.006005446,0.004856355,0.0028858946,0.000405304],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002174743,0.0000188653,0.00071724446,0.9547601,0.014635247,0.00009911244,0.0005169757,0.00026550412,0.0000641188,0.0015425673,0.0020211563,0.025141569],"study_design_scores_gemma":[0.00022689512,0.00011734355,0.0016262016,0.9313588,0.045581613,0.0001928797,0.0007200596,0.000213613,0.00012775662,0.0026037258,0.017176943,0.000054239474],"about_ca_topic_score_codex":0.0067725987,"about_ca_topic_score_gemma":0.015295806,"teacher_disagreement_score":0.08765125,"about_ca_system_score_codex":0.0110855345,"about_ca_system_score_gemma":0.02962602,"threshold_uncertainty_score":0.46354967},"labels":[],"label_agreement":null},{"id":"W4378745433","doi":"10.1007/s41669-023-00422-1","title":"Perceptions and Attitudes Regarding Medical Device Development in Canada Among Canadian Innovators: A Qualitative Study","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre for Advancing Health Outcomes; St. Paul's Hospital; Institute of Health Economics; University of Calgary; University of British Columbia","funders":"","keywords":"Perception; Focus group; Qualitative research; Process (computing); Health technology; Marketing; Psychology; Public relations; Health care; Business; Medical education; Medicine; Political science; Sociology; Economic growth; Economics","score_opus":0.3893493514127117,"score_gpt":0.5220560011702162,"score_spread":0.1327066497575045,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378745433","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873585,0.00090913917,0.00035418497,0.0028431553,0.000039475748,0.00011342953,0.00032775413,0.000013319387,0.008041027],"genre_scores_gemma":[0.992769,0.0012126674,0.00038896894,0.0010968737,0.000011965847,0.000066708315,0.00010458224,0.000011621102,0.0043376363],"study_design_codex":"qualitative","study_design_gemma":"qualitative","domain_scores_codex":[0.9962424,0.0008000593,0.00011950483,0.0003179898,0.001098442,0.001421613],"domain_scores_gemma":[0.9906775,0.0027111454,0.0007796361,0.00013750637,0.0031547933,0.0025395004],"candidate_categories":["sts"],"consensus_categories":[],"category_scores_codex":[0.0045766723,0.00036008641,0.0005549632,0.001977296,0.014609353,0.0044564726,0.0014187706,0.0015358691,0.0033945583],"category_scores_gemma":[0.008055367,0.0003999866,0.00051903195,0.0031649661,0.005767086,0.0011873783,0.0026481648,0.0021200387,0.00024591072],"study_design_candidate":"qualitative","study_design_consensus":"qualitative","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0000829147,0.00008821671,0.04544566,0.00024801114,0.000011588821,0.0014728834,0.9367233,0.00009340532,0.001489172,0.0014236703,0.002278192,0.0106430035],"study_design_scores_gemma":[0.0000073067727,0.00008758278,0.03563418,0.00025646325,0.000016835214,0.00035995446,0.935136,0.00020636567,0.00035473434,0.00010444687,0.0277636,0.00007238322],"about_ca_topic_score_codex":0.96539223,"about_ca_topic_score_gemma":0.9711032,"teacher_disagreement_score":0.98539066,"about_ca_system_score_codex":0.05587564,"about_ca_system_score_gemma":0.090088286,"threshold_uncertainty_score":0.40540808},"labels":[],"label_agreement":null},{"id":"W4382139156","doi":"10.1007/s41669-023-00427-w","title":"Cost Effectiveness of Different Platelet Preparation, Storage, Selection and Dosing Methods in Platelet Transfusion: A Systematic Review","year":2023,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"Blood transfusion and management","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Mount Sinai Hospital; University of Alberta; Alberta Environment and Protected Areas","funders":"","keywords":"Dosing; Platelet transfusion; Platelet; Medicine; Selection (genetic algorithm); Blood preservation; Blood transfusion; Intensive care medicine; Pharmacology; Computer science; Internal medicine; Andrology; Machine learning","score_opus":0.1402910018837543,"score_gpt":0.49555661481741897,"score_spread":0.35526561293366465,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4382139156","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0016081083,0.9969283,0.00016515679,0.00025569473,0.000078130775,0.00021248983,0.0004385143,0.0000069110893,0.000306683],"genre_scores_gemma":[0.031373788,0.9661859,0.00085557037,0.00044665622,0.000093596645,0.0005911531,0.0003262468,0.000009257729,0.00011780012],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9892077,0.005019468,0.0029009657,0.00063785707,0.0019210764,0.00031287404],"domain_scores_gemma":[0.961873,0.030919766,0.004947087,0.00028807914,0.0017359277,0.0002361361],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009948562,0.0020125282,0.009294343,0.007913069,0.0005345405,0.003611659,0.0019095596,0.0023763923,0.0052022785],"category_scores_gemma":[0.04524578,0.0011281886,0.015052615,0.007290326,0.0008419349,0.002336952,0.0013848395,0.0018065588,0.00025885995],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008583379,0.000035385023,0.0006197778,0.9345208,0.023131367,0.00006214614,0.000059706676,0.00037821528,0.00008554259,0.00038228292,0.00094402593,0.038922444],"study_design_scores_gemma":[0.00097318634,0.00058259635,0.0044626608,0.7927899,0.18606226,0.00038770144,0.0002007194,0.00040275164,0.0002863363,0.0007902307,0.0129975425,0.00006418584],"about_ca_topic_score_codex":0.008215239,"about_ca_topic_score_gemma":0.01722933,"teacher_disagreement_score":0.009948562,"about_ca_system_score_codex":0.006113268,"about_ca_system_score_gemma":0.00890951,"threshold_uncertainty_score":0.052613676},"labels":[],"label_agreement":null},{"id":"W4387077281","doi":"10.1007/s41669-023-00441-y","title":"Estimating Cumulative Health Care Costs of Childhood and Adolescence Autism Spectrum Disorder in Ontario, Canada: A Population-Based Incident Cohort Study","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Autism Spectrum Disorder Research","field":"Neuroscience","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Toronto Rehabilitation Institute; Institute for Clinical Evaluative Sciences; Centre for Addiction and Mental Health","funders":"","keywords":"Cumulative incidence; Medicine; Inverse probability weighting; Health care; Population; Cohort; Demography; Pediatrics; Incidence (geometry); Autism spectrum disorder; Propensity score matching; Autism; Environmental health; Psychiatry; Surgery; Internal medicine","score_opus":0.030199127256097448,"score_gpt":0.354877130522664,"score_spread":0.32467800326656654,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387077281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.95995665,0.0013382729,0.00073921744,0.0006096364,0.000022461943,0.00036170363,0.034761436,0.0000307523,0.0021799451],"genre_scores_gemma":[0.9784752,0.0017652815,0.0017053332,0.00021148729,0.000020112331,0.0003056348,0.015890604,0.000016085032,0.0016104181],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99827766,0.00017641671,0.00017253854,0.00027777837,0.00071023626,0.0003853997],"domain_scores_gemma":[0.99553406,0.00027626386,0.0013321086,0.0003099404,0.0020230438,0.0005244672],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018379907,0.00055339385,0.0006854316,0.00291702,0.0022043241,0.001437943,0.00214685,0.0005686334,0.001677808],"category_scores_gemma":[0.0048174527,0.00068592135,0.0013982242,0.0063381135,0.00058486476,0.0005407639,0.0011672915,0.0009164727,0.00027061047],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000032478027,0.000019980911,0.9966743,0.000034878078,0.00013163326,0.000051259634,0.00021137152,0.00018783339,0.000028012899,0.000071360984,0.0010364546,0.0015204272],"study_design_scores_gemma":[0.000014416189,0.000015910631,0.997846,0.000042437736,0.000082760154,0.000048717557,0.00035097805,0.00059664896,0.000017340737,0.000027036724,0.0009487923,0.0000088785155],"about_ca_topic_score_codex":0.99409336,"about_ca_topic_score_gemma":0.9948147,"teacher_disagreement_score":0.039813485,"about_ca_system_score_codex":0.039813485,"about_ca_system_score_gemma":0.03434444,"threshold_uncertainty_score":0.28886843},"labels":[],"label_agreement":null},{"id":"W4387530829","doi":"10.1007/s41669-023-00444-9","title":"Real-World Cost Effectiveness of a Policy of KRAS Testing to Inform Cetuximab or Panitumumab for Third-Line Therapy of Metastatic Colorectal Cancer in British Columbia, Canada","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver Coastal Health Research Institute; Vancouver Coastal Health; Canadian Centre for Applied Research in Cancer Control; University of British Columbia; Simon Fraser University; BC Cancer Agency","funders":"Canadian Institutes of Health Research; Genome British Columbia; Canadian Cancer Society; Canadian Centre for Applied Research in Cancer Control; Genome Canada","keywords":"Panitumumab; Cetuximab; KRAS; Colorectal cancer; Medicine; Oncology; Internal medicine; Family medicine; Cancer","score_opus":0.09380784200263412,"score_gpt":0.4210999267675946,"score_spread":0.3272920847649605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387530829","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97793657,0.0018365455,0.0010091319,0.00326544,0.00005650456,0.00034273413,0.010030302,0.00005584945,0.005466849],"genre_scores_gemma":[0.9962561,0.00041618245,0.0005318721,0.00023047278,0.000009223448,0.00005106831,0.0017550943,0.0000064390783,0.0007434057],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9961204,0.0014510343,0.00017252497,0.00040580257,0.0005393841,0.0013108696],"domain_scores_gemma":[0.9919927,0.0034667852,0.0012266113,0.00022975911,0.0018805197,0.0012036153],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036691274,0.000761085,0.0009479933,0.00096513634,0.0011379333,0.0023472903,0.0019007953,0.0009839418,0.003171748],"category_scores_gemma":[0.0147422245,0.00048751244,0.0012795676,0.0020773485,0.0011628191,0.00062136824,0.0010817786,0.0019959575,0.00017346903],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008823918,0.001322756,0.34427255,0.0011233732,0.0030159946,0.0009679087,0.0003912083,0.58222985,0.00087708107,0.008196302,0.01820553,0.030573567],"study_design_scores_gemma":[0.003406076,0.0017088306,0.46346274,0.000617577,0.0019527335,0.00034272898,0.0027043533,0.5111973,0.0010273082,0.003946457,0.009321298,0.00031259845],"about_ca_topic_score_codex":0.9876368,"about_ca_topic_score_gemma":0.9823099,"teacher_disagreement_score":0.101905845,"about_ca_system_score_codex":0.101905845,"about_ca_system_score_gemma":0.052431766,"threshold_uncertainty_score":0.73938215},"labels":[],"label_agreement":null},{"id":"W4388790771","doi":"10.1007/s41669-023-00453-8","title":"Economic Burden of Delayed Diagnosis in Patients with Pulmonary Arterial Hypertension (PAH)","year":2023,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs","keywords":"Medicine; Confidence interval; Incidence (geometry); Intensive care unit; Pediatrics; Emergency medicine; Diagnosis code; Internal medicine; Population","score_opus":0.034491389858649295,"score_gpt":0.32302525963155976,"score_spread":0.28853386977291046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388790771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98828006,0.00398742,0.00023875435,0.0028202476,0.000071202274,0.000020578012,0.0034505378,0.0000047590133,0.0011264859],"genre_scores_gemma":[0.997656,0.0008879324,0.00011644339,0.00015697318,0.000056482007,0.000010465334,0.0010438142,0.0000012652738,0.00007051362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9985189,0.00066210603,0.00016686867,0.00013200624,0.00023790033,0.00028223597],"domain_scores_gemma":[0.99402595,0.0013633831,0.0034662562,0.000109740016,0.00040880826,0.0006258444],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011818964,0.00018327901,0.00033079577,0.0007683804,0.00027699248,0.0009196448,0.0004230302,0.0004464947,0.0019329468],"category_scores_gemma":[0.007920889,0.0001605798,0.0007750213,0.0012015244,0.00026774153,0.0005346867,0.0009209162,0.0010730273,0.00011732375],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017216582,0.000049198123,0.9926674,0.00007420453,0.000212566,0.00014814638,0.000039281775,0.0007945742,0.00003172413,0.00023717884,0.0010356928,0.004537947],"study_design_scores_gemma":[0.000037326095,0.00013857789,0.9930189,0.00018125317,0.0001315047,0.0006651466,0.0004687813,0.0036837496,0.000052477735,0.00038920584,0.0012204621,0.000012546571],"about_ca_topic_score_codex":0.018286154,"about_ca_topic_score_gemma":0.017192654,"teacher_disagreement_score":0.018286154,"about_ca_system_score_codex":0.0017230453,"about_ca_system_score_gemma":0.0011693136,"threshold_uncertainty_score":0.03635949},"labels":[],"label_agreement":null},{"id":"W4390706466","doi":"10.1007/s41669-023-00464-5","title":"A Systematic Literature Review of Health-Related Quality of Life Outcomes and Associated Utility Values in Relapsed and/or Refractory Large B Cell Lymphoma","year":2024,"lang":"en","type":"review","venue":"PharmacoEconomics - Open","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Quality of life (healthcare); Population; Rituximab; Health care; Systematic review; MEDLINE; Oncology; Family medicine; Lymphoma; Internal medicine; Environmental health; Cancer; Immunotherapy; Nursing","score_opus":0.13180303865277276,"score_gpt":0.47445124690915247,"score_spread":0.3426482082563797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390706466","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0037516674,0.99208474,0.0003452913,0.00042750733,0.00010916865,0.0010593317,0.0015670165,0.000013196382,0.0006422038],"genre_scores_gemma":[0.046971597,0.946587,0.0019243315,0.00081865006,0.00010058161,0.002528707,0.0008730956,0.000010677444,0.00018542958],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9810884,0.006799482,0.008206544,0.001093741,0.002357218,0.00045460858],"domain_scores_gemma":[0.9416889,0.039835468,0.0123336995,0.0007496375,0.004897078,0.000495336],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.016370514,0.001763374,0.010176067,0.02314499,0.0008675271,0.0034238477,0.0022121302,0.001995929,0.0045760856],"category_scores_gemma":[0.07320826,0.0010743283,0.008230776,0.022192024,0.0012792837,0.002868574,0.002347104,0.0011301037,0.00030349146],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00017303052,0.0000117867285,0.0010681116,0.97230893,0.007348743,0.00013696303,0.00019210465,0.000095812036,0.00008694068,0.00017358671,0.0007204674,0.017683443],"study_design_scores_gemma":[0.00029119232,0.00025779492,0.006001147,0.9090975,0.0733032,0.00043709725,0.00041300067,0.00010427863,0.00014418666,0.00031747262,0.009593158,0.000040068182],"about_ca_topic_score_codex":0.009325678,"about_ca_topic_score_gemma":0.023308445,"teacher_disagreement_score":0.02314499,"about_ca_system_score_codex":0.0069321194,"about_ca_system_score_gemma":0.017687278,"threshold_uncertainty_score":0.08657664},"labels":[],"label_agreement":null},{"id":"W4393183309","doi":"10.1007/s41669-024-00481-y","title":"A Canadian Simulation Model for Major Depressive Disorder: Study Protocol","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Treatment of Major Depression","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Fraser Health; University of British Columbia; BC Centre for Disease Control; Vancouver Coastal Health; Vancouver Coastal Health Research Institute; Simon Fraser University","funders":"Genome British Columbia; Michael Smith Health Research BC; Genome Canada","keywords":"Major depressive disorder; Psychological intervention; Flexibility (engineering); Protocol (science); Depression (economics); Quality of life (healthcare); Health care; Microsimulation; Medicine; Economic evaluation; Psychiatry; Alternative medicine; Engineering; Nursing","score_opus":0.05893575928001667,"score_gpt":0.44301641223820665,"score_spread":0.38408065295819,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4393183309","genre_codex":"dataset","genre_gemma":"protocol","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"protocol","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.16036166,0.0041186493,0.2155922,0.010650102,0.00092982897,0.09959461,0.33120313,0.0019382036,0.17561154],"genre_scores_gemma":[0.63499963,0.0029331814,0.16957566,0.0016685857,0.000092963455,0.11309304,0.05724228,0.00029164882,0.020102976],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99769455,0.0013736305,0.00011265665,0.00026341807,0.00024113427,0.00031471648],"domain_scores_gemma":[0.986978,0.0077216746,0.00057535275,0.00047476517,0.003739599,0.0005106302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006325963,0.0015944056,0.0009910247,0.0015084845,0.0011564366,0.0015488975,0.004391511,0.0018788859,0.040252015],"category_scores_gemma":[0.024073899,0.00082074077,0.0015861124,0.0025010365,0.00074897916,0.0007397383,0.0014466661,0.0021815412,0.0015753072],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016707152,0.0005341225,0.0070917583,0.0015494132,0.00039958744,0.0002833029,0.00025300228,0.87813234,0.00019891035,0.04369927,0.04869165,0.017495902],"study_design_scores_gemma":[0.0063691833,0.00045681256,0.0043386985,0.0009040236,0.000618062,0.00008014217,0.00050694874,0.8858977,0.00041691028,0.026223358,0.07402154,0.00016651802],"about_ca_topic_score_codex":0.561254,"about_ca_topic_score_gemma":0.48952007,"teacher_disagreement_score":0.9840999,"about_ca_system_score_codex":0.01590007,"about_ca_system_score_gemma":0.03285342,"threshold_uncertainty_score":0.8826597},"labels":[],"label_agreement":null},{"id":"W4394713652","doi":"10.1007/s41669-024-00483-w","title":"Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Herpesvirus Infections and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"GlaxoSmithKline Biologicals","keywords":"Medicine; Cost effectiveness; Quality-adjusted life year; Cost-effectiveness analysis; Vaccination; Vaccine efficacy; Demography; Public health; Economic evaluation; Cost–benefit analysis; Health care; Pediatrics; Virology; Economics","score_opus":0.0365584503831496,"score_gpt":0.3928126937570696,"score_spread":0.35625424337392003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4394713652","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55913407,0.18263263,0.0039258287,0.013867794,0.0007767816,0.00050287804,0.19237135,0.00030373927,0.046484947],"genre_scores_gemma":[0.94460315,0.027001379,0.0022624067,0.0011667656,0.00013037099,0.000077096694,0.023371264,0.000023575672,0.0013640375],"study_design_codex":"observational","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.998329,0.00024456295,0.00012226205,0.00012966436,0.0008744585,0.00030010863],"domain_scores_gemma":[0.9964353,0.0004761539,0.0004545438,0.000086547014,0.0023158896,0.00023150581],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003067239,0.0007796413,0.000830411,0.0026422536,0.0007506579,0.0018318197,0.0012340812,0.000694061,0.0031723646],"category_scores_gemma":[0.010336315,0.00030380816,0.0029570942,0.002897817,0.00034597973,0.0007572049,0.00066855,0.0009545784,0.00022074039],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023345335,0.00021561037,0.68734115,0.0054167113,0.008777893,0.0005195262,0.00051724905,0.08387825,0.00042666416,0.0070825457,0.050625883,0.15286398],"study_design_scores_gemma":[0.00070365466,0.0003624269,0.8921766,0.0034492747,0.0092597725,0.0004987401,0.00081973296,0.042309105,0.0006294297,0.0023305244,0.04724263,0.0002181658],"about_ca_topic_score_codex":0.983125,"about_ca_topic_score_gemma":0.9768941,"teacher_disagreement_score":0.04712393,"about_ca_system_score_codex":0.04712393,"about_ca_system_score_gemma":0.04503022,"threshold_uncertainty_score":0.34190965},"labels":[],"label_agreement":null},{"id":"W4396576727","doi":"10.1007/s41669-024-00484-9","title":"Cancer-Specific Health Utilities: Evaluation of Core Measurement Properties of the EORTC QLU-C10D in Lung Cancer Patients—Data from Four Multicentre LUX-Lung Trials, Applying Six Country Tariffs","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"European Organisation for Research and Treatment of Cancer","keywords":"Lung cancer; Quality of life (healthcare); EQ-5D; Medicine; Construct validity; Cancer; Physical therapy; Disease; Psychometrics; Clinical psychology; Health related quality of life; Oncology; Nursing; Internal medicine","score_opus":0.7914805543456943,"score_gpt":0.5302336988651476,"score_spread":0.2612468554805467,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4396576727","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935927,0.0024241074,0.00078915275,0.00007126679,0.000008355911,0.00056177075,0.0019594836,0.000006702813,0.0005864732],"genre_scores_gemma":[0.9946731,0.00021982566,0.00087875186,0.00006304715,0.000010329747,0.0006792081,0.0034022985,0.0000061725045,0.000067306144],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.97316587,0.021217033,0.002394862,0.0010126906,0.0018139208,0.0003955796],"domain_scores_gemma":[0.9563599,0.02698954,0.010926868,0.0027203653,0.0023903043,0.00061294966],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.04559607,0.000570447,0.0014963085,0.0020147583,0.00030705816,0.0010379336,0.0007929398,0.0006837633,0.0011505861],"category_scores_gemma":[0.052016094,0.00030957727,0.0023041945,0.0036245482,0.00086118665,0.0010011428,0.0016666165,0.0006439317,0.00018486986],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.052215792,0.0009233843,0.8902109,0.0016994848,0.0071839103,0.0001746707,0.00056363374,0.0074343802,0.0010842298,0.00031706484,0.0012697382,0.03692279],"study_design_scores_gemma":[0.010091645,0.011593461,0.96723837,0.00022711993,0.0030932825,0.0005166193,0.00030118303,0.003952987,0.0009355248,0.00029860847,0.0016661588,0.000085071755],"about_ca_topic_score_codex":0.0014731935,"about_ca_topic_score_gemma":0.0016288442,"teacher_disagreement_score":0.04559607,"about_ca_system_score_codex":0.0011782516,"about_ca_system_score_gemma":0.00066623546,"threshold_uncertainty_score":0.24113798},"labels":[],"label_agreement":null},{"id":"W4400731480","doi":"10.1007/s41669-024-00502-w","title":"Correction: Updated Public Health Impact and Cost Effectiveness of Recombinant Zoster Vaccine in Canadian Adults Aged 50 Years and Older","year":2024,"lang":"en","type":"erratum","venue":"PharmacoEconomics - Open","topic":"Herpesvirus Infections and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Public health; Recombinant DNA; Gerontology; Environmental health; Nursing; Biology; Genetics","score_opus":0.03135076596778646,"score_gpt":0.37623301049223784,"score_spread":0.3448822445244514,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400731480","genre_codex":"editorial","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"other","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0001590176,0.0036959639,0.00017529994,0.082590885,0.8848765,0.00010535278,0.022676567,0.0002223688,0.0054980726],"genre_scores_gemma":[0.018350996,0.030993832,0.003640194,0.2247838,0.51254696,0.00096835365,0.028629648,0.0012707737,0.17881544],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9897361,0.0007930466,0.0013187842,0.0006697287,0.006136737,0.0013456563],"domain_scores_gemma":[0.9301889,0.01129375,0.0024034332,0.0016536963,0.05149879,0.0029614682],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009184945,0.0036094787,0.0042128307,0.00794926,0.0034437908,0.0060384255,0.0071426397,0.0094721075,0.055065993],"category_scores_gemma":[0.12153401,0.0019172848,0.004765354,0.009366308,0.0023282187,0.002246157,0.0018379217,0.013417817,0.01393731],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00001807827,0.0000017855632,0.00004349712,0.00009600523,0.000015750276,0.000026543677,0.000005746454,0.000022055105,0.0000025063275,0.00009248331,0.998628,0.0010477119],"study_design_scores_gemma":[0.00064345106,0.0000219751,0.004032911,0.0022803238,0.000467812,0.00019540297,0.00014387145,0.00035442854,0.0001287996,0.0007611997,0.9908806,0.00008915785],"about_ca_topic_score_codex":0.79015905,"about_ca_topic_score_gemma":0.731815,"teacher_disagreement_score":0.20984095,"about_ca_system_score_codex":0.029489279,"about_ca_system_score_gemma":0.06769003,"threshold_uncertainty_score":0.42215347},"labels":[],"label_agreement":null},{"id":"W4401109065","doi":"10.1007/s41669-024-00513-7","title":"Evaluating Cost-Effectiveness of Antiretroviral Therapy over Time: A Cohort and Cost-Effectiveness Study","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"HIV/AIDS Research and Interventions","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Health Economics","funders":"Novocure; Gilead Sciences","keywords":"Antiretroviral therapy; Cost effectiveness; Cohort; Medicine; Human immunodeficiency virus (HIV); Intensive care medicine; Risk analysis (engineering); Viral load; Internal medicine; Virology","score_opus":0.12949161976690404,"score_gpt":0.5175589457037367,"score_spread":0.3880673259368327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401109065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9699387,0.006577256,0.011831476,0.00042314982,0.0001390831,0.002335524,0.007051986,0.000039244373,0.0016636498],"genre_scores_gemma":[0.9871689,0.0019385865,0.005099702,0.0002063146,0.000060662802,0.0011574712,0.0040362533,0.000015158918,0.00031702695],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99108535,0.005652025,0.0007860009,0.0011769658,0.00084664917,0.0004529449],"domain_scores_gemma":[0.9762512,0.014168388,0.00511151,0.0022229587,0.0014971409,0.0007487825],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.024762968,0.0014217788,0.0017745772,0.0019766383,0.0005409252,0.0022811475,0.0015077551,0.0019200845,0.0028256155],"category_scores_gemma":[0.045766868,0.0007789469,0.008904235,0.0017728169,0.00055864017,0.0018538905,0.0015722443,0.0014684659,0.00030046853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05208761,0.004582891,0.6294071,0.0029658827,0.09080932,0.00094659836,0.00050501665,0.13961506,0.0012272092,0.0061346684,0.0027229618,0.06899564],"study_design_scores_gemma":[0.016184129,0.033829834,0.5172132,0.0029297858,0.06430033,0.0034091626,0.0010785483,0.33499786,0.0020784338,0.010640089,0.012599891,0.0007386883],"about_ca_topic_score_codex":0.009637461,"about_ca_topic_score_gemma":0.0045252303,"teacher_disagreement_score":0.024762968,"about_ca_system_score_codex":0.0031097177,"about_ca_system_score_gemma":0.002487578,"threshold_uncertainty_score":0.1309607},"labels":[],"label_agreement":null},{"id":"W4401322712","doi":"10.1007/s41669-024-00511-9","title":"Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers’ Submissions and a Comparison between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; Impact; McMaster University Medical Centre","funders":"","keywords":"Reimbursement; Agency (philosophy); Health technology; Business; Medicine; Health care; Sociology; Economic growth; Economics; Social science","score_opus":0.5233009372616017,"score_gpt":0.6065075666626815,"score_spread":0.08320662940107981,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401322712","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":"evaluation","domain_gemma":"reporting","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":"reporting","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.047746465,0.2540002,0.042809635,0.39146632,0.041832473,0.017987203,0.13528472,0.0015152696,0.06735779],"genre_scores_gemma":[0.53667074,0.09844122,0.13537633,0.12325903,0.013487441,0.030307336,0.04814087,0.0021761118,0.012140917],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.2646042,0.20264213,0.19998237,0.016531456,0.30940667,0.006833174],"domain_scores_gemma":[0.037798695,0.42392108,0.08488083,0.028183036,0.42175853,0.0034577618],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.5774264,0.0020443003,0.003574063,0.030817296,0.0063491263,0.01793588,0.008917366,0.0049321945,0.0039702347],"category_scores_gemma":[0.87835157,0.0026745764,0.007186888,0.039906163,0.007422799,0.0040788217,0.0059344918,0.0065730205,0.0010508387],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001974997,0.00010241533,0.053674676,0.06910775,0.0073993206,0.0005863991,0.011198512,0.0041149915,0.0006104542,0.021487,0.58319575,0.24654774],"study_design_scores_gemma":[0.0011568362,0.00022888751,0.09488977,0.15336752,0.005671416,0.0003925621,0.003264429,0.0042436956,0.0030223501,0.011974728,0.72089875,0.00088896975],"about_ca_topic_score_codex":0.5973928,"about_ca_topic_score_gemma":0.5405575,"teacher_disagreement_score":0.920281,"about_ca_system_score_codex":0.07971899,"about_ca_system_score_gemma":0.25220406,"threshold_uncertainty_score":0.80995643},"labels":[],"label_agreement":null},{"id":"W4402602582","doi":"10.1007/s41669-024-00522-6","title":"Publisher Correction: Health Technology Assessment Reports for Non-Oncology Medications in Canada from 2018 to 2022: Methodological Critiques on Manufacturers’ Submissions and a Comparison Between Manufacturer and Canadian Agency for Drugs and Technologies in Health (CADTH) Analyses","year":2024,"lang":"en","type":"erratum","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; Impact; McMaster University Medical Centre","funders":"","keywords":"Agency (philosophy); Medicine; Engineering ethics; Engineering; Sociology; Social science","score_opus":0.47457637957924936,"score_gpt":0.5833406924088185,"score_spread":0.10876431282956911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4402602582","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":"methods","domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025294165,0.0019434293,0.0005962874,0.12392359,0.84773195,0.00009290325,0.013007836,0.0005834234,0.01186762],"genre_scores_gemma":[0.019287912,0.011419013,0.009244226,0.24345079,0.2065877,0.00085804035,0.015486999,0.003676526,0.48998877],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9510986,0.002998162,0.0073860288,0.002329747,0.03340509,0.0027823958],"domain_scores_gemma":[0.6209465,0.052948885,0.008625675,0.011353243,0.30094197,0.005183691],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.022586854,0.0026614796,0.0034697044,0.014523084,0.008701318,0.013310216,0.007930378,0.010397118,0.051310614],"category_scores_gemma":[0.2626994,0.0026213476,0.0031444468,0.015609901,0.0048652445,0.0028491195,0.0028812196,0.01690331,0.023992343],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00000865269,0.0000019018897,0.00004878968,0.000048582555,0.000006286051,0.000024064311,0.00001938069,0.000026168362,0.0000039092147,0.00040676296,0.9978948,0.0015107163],"study_design_scores_gemma":[0.00006235347,0.000007580951,0.0017045825,0.0008084976,0.0000700754,0.000070335256,0.0001829117,0.0002456372,0.0001488648,0.0011337724,0.9955006,0.000064751825],"about_ca_topic_score_codex":0.84708744,"about_ca_topic_score_gemma":0.8430958,"teacher_disagreement_score":0.9774131,"about_ca_system_score_codex":0.04678376,"about_ca_system_score_gemma":0.10986627,"threshold_uncertainty_score":0.33944154},"labels":[],"label_agreement":null},{"id":"W4403226544","doi":"10.1007/s41669-024-00523-5","title":"Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Inflammatory Bowel Disease","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"McMaster University; Population Health Research Institute; Takeda (Canada)","funders":"Takeda Canada","keywords":"Vedolizumab; Ulcerative colitis; Crohn's disease; Medicine; Disease; Inflammatory bowel disease; Gastroenterology; Internal medicine; Dermatology","score_opus":0.06370502091376154,"score_gpt":0.37473293745155084,"score_spread":0.3110279165377893,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403226544","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9776552,0.0057748468,0.0029639911,0.0011281263,0.000036654263,0.0009099746,0.009122833,0.000038329177,0.0023699391],"genre_scores_gemma":[0.9923558,0.0015617396,0.0020915451,0.00019834407,0.000010130757,0.00019705763,0.0031620974,0.000010314905,0.0004129357],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9934738,0.003993342,0.00036612933,0.00042976282,0.0008140914,0.0009229326],"domain_scores_gemma":[0.97245425,0.018089302,0.0038675708,0.0007665187,0.0033340652,0.0014883429],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.010701251,0.0013369942,0.0023836768,0.002176374,0.00082337076,0.00214935,0.0019792996,0.0012465056,0.0022097677],"category_scores_gemma":[0.03173159,0.0009835758,0.0065595894,0.0032598206,0.0011472546,0.00088134076,0.0013802652,0.0015297296,0.000110829315],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01902111,0.00069745834,0.18101272,0.0020631177,0.013591228,0.0006152642,0.00029108708,0.7526785,0.00035809205,0.0049595856,0.0030761892,0.021635681],"study_design_scores_gemma":[0.0066176634,0.0033294207,0.16523054,0.0011273316,0.014176283,0.0004914602,0.0010136386,0.8004374,0.00064088684,0.0029576244,0.003661748,0.0003160177],"about_ca_topic_score_codex":0.9173464,"about_ca_topic_score_gemma":0.84661204,"teacher_disagreement_score":0.08265358,"about_ca_system_score_codex":0.055469904,"about_ca_system_score_gemma":0.035280466,"threshold_uncertainty_score":0.40246415},"labels":[],"label_agreement":null},{"id":"W4404514253","doi":"10.1007/s41669-024-00538-y","title":"Health Economic Evaluation of Antimicrobial Stewardship, Procalcitonin Testing, and Rapid Blood Culture Identification in Sepsis Care: A 90-Day Model-Based, Cost-Utility Analysis","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Sepsis Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Hospital Edmonton; University of Calgary; University of Alberta Hospital; Alberta Health; Foothills Medical Centre; Institute of Health Economics; University of Alberta; Alberta Energy; Alberta Health Services","funders":"bioMérieux; Alberta Innovates; Alberta Health Services","keywords":"Medicine; Antimicrobial stewardship; Procalcitonin; Cost effectiveness; Emergency medicine; Blood culture; Intensive care unit; Sepsis; Cost-effectiveness analysis; Health care; Intensive care medicine; Internal medicine; Antibiotic resistance; Antibiotics","score_opus":0.1367678741257744,"score_gpt":0.4476165044249941,"score_spread":0.3108486302992197,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404514253","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9626808,0.007058716,0.019513778,0.0014614495,0.00009595642,0.0014337321,0.0031937666,0.000119300734,0.004442448],"genre_scores_gemma":[0.9941187,0.0006172966,0.004029597,0.00009445323,0.00001340833,0.00026020146,0.0006220756,0.000007563521,0.0002368226],"study_design_codex":"simulation_or_modeling","study_design_gemma":"simulation_or_modeling","domain_scores_codex":[0.99102354,0.0071118046,0.00024328945,0.00036641493,0.0006512111,0.0006038019],"domain_scores_gemma":[0.98686266,0.010265809,0.0009797584,0.00029131802,0.00098044,0.0006199878],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.012897778,0.0019792044,0.0028634,0.002474919,0.00048642597,0.0019098013,0.0020291246,0.001336152,0.0022039446],"category_scores_gemma":[0.025191788,0.0009261175,0.0040624617,0.0020909668,0.0008427359,0.0014248006,0.0014521575,0.0014557755,0.000121170655],"study_design_candidate":"simulation_or_modeling","study_design_consensus":"simulation_or_modeling","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008634273,0.0009624679,0.01560847,0.0009324947,0.0037372047,0.0001207695,0.00005426657,0.95477086,0.00028904784,0.0017764933,0.0006850011,0.012428699],"study_design_scores_gemma":[0.002116279,0.0035400684,0.012825797,0.00018713625,0.0028936353,0.00007960491,0.00009478169,0.97588706,0.00028220157,0.0015519304,0.00047679569,0.00006473481],"about_ca_topic_score_codex":0.13027745,"about_ca_topic_score_gemma":0.060654312,"teacher_disagreement_score":0.13027745,"about_ca_system_score_codex":0.019342309,"about_ca_system_score_gemma":0.010347662,"threshold_uncertainty_score":0.25903833},"labels":[],"label_agreement":null},{"id":"W4404905928","doi":"10.1007/s41669-024-00541-3","title":"Economic Evaluation of Total Knee Replacement Compared with Non-Surgical Management for Knee Osteoarthritis in India","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Total Knee Arthroplasty Outcomes","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Indigenous Peoples' Health; Ministry of Health and Family Welfare","keywords":"Medicine; Osteoarthritis; Total knee replacement; Quality-adjusted life year; Economic evaluation; Physical therapy; Implant; Knee replacement; Arthroplasty; Cost effectiveness; Surgery","score_opus":0.027701895563404584,"score_gpt":0.35563596999736913,"score_spread":0.32793407443396455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404905928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93580055,0.020821175,0.007997794,0.0036098661,0.00020186818,0.0012127822,0.0032399946,0.00006565092,0.027050234],"genre_scores_gemma":[0.9960555,0.0017550531,0.0011090429,0.00012714617,0.00001800182,0.00013949831,0.0003119319,0.0000060553534,0.00047781982],"study_design_codex":"simulation_or_modeling","study_design_gemma":"nonrandomized_trial","domain_scores_codex":[0.99037325,0.0077654994,0.00025676127,0.0002011145,0.00081935694,0.0005840151],"domain_scores_gemma":[0.991211,0.006259638,0.0011872674,0.00020053316,0.00071235467,0.0004291333],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.008398074,0.0009063494,0.0010318687,0.0015923036,0.0003606158,0.002672556,0.0010513123,0.0007367992,0.003510369],"category_scores_gemma":[0.016086286,0.00041488424,0.0029943106,0.002058343,0.00076622743,0.0010314672,0.0013651547,0.0012895149,0.00013549405],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020421097,0.0016859812,0.07380136,0.008753124,0.0068075806,0.0009479969,0.0003001416,0.7886607,0.0017281836,0.018690648,0.0048312424,0.07337189],"study_design_scores_gemma":[0.007222374,0.028208997,0.20302202,0.005908161,0.01368035,0.0030024701,0.0032908919,0.6885542,0.0056892303,0.018871333,0.02207416,0.0004758319],"about_ca_topic_score_codex":0.014893953,"about_ca_topic_score_gemma":0.008482893,"teacher_disagreement_score":0.014893953,"about_ca_system_score_codex":0.009225583,"about_ca_system_score_gemma":0.0053845015,"threshold_uncertainty_score":0.06693655},"labels":[],"label_agreement":null},{"id":"W4405460373","doi":"10.1007/s41669-024-00537-z","title":"Incorporating Resource Constraints in Health Economic Evaluations: Overview and Methodological Considerations","year":2024,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"F. Hoffmann-La Roche; Roche","keywords":"Resource (disambiguation); Management science; Psychological intervention; Health care; Health technology; Set (abstract data type); Risk analysis (engineering); Economic evaluation; Computer science; Intervention (counseling); Knowledge management; Process management; Environmental economics; Business; Medicine; Economics; Nursing; Microeconomics","score_opus":0.7165022102291071,"score_gpt":0.6053250367160649,"score_spread":0.11117717351304224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405460373","genre_codex":"methods","genre_gemma":"methods","domain_codex":"methods","domain_gemma":"methods","model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"methods","genre_consensus":"methods","domain_candidate":"methods","domain_consensus":"methods","prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0025889466,0.08091788,0.882251,0.017794102,0.00072637305,0.0071316427,0.00037114014,0.00012675028,0.00809213],"genre_scores_gemma":[0.08472759,0.043678116,0.84563166,0.0043751583,0.0010314395,0.019456156,0.0002464358,0.00013307355,0.0007203149],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.34089047,0.5969359,0.037058715,0.0043878034,0.018707078,0.0020200135],"domain_scores_gemma":[0.20111512,0.7553173,0.017483355,0.009768473,0.01558347,0.0007323379],"candidate_categories":["metaresearch"],"consensus_categories":["metaresearch"],"category_scores_codex":[0.4695537,0.0048999945,0.0073815417,0.013124056,0.002420467,0.017496428,0.0066081327,0.008045192,0.0027863255],"category_scores_gemma":[0.614051,0.0038515471,0.008860871,0.018027123,0.010779029,0.015597221,0.010155167,0.014013065,0.0004638364],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004315588,0.00032926034,0.004591469,0.02380155,0.0037686578,0.00043328403,0.0019396011,0.075349115,0.00025235637,0.6896166,0.005078599,0.19440795],"study_design_scores_gemma":[0.0005549395,0.00048770168,0.0021067073,0.047307413,0.002234223,0.00038684715,0.0013418429,0.09108765,0.0013444381,0.80074435,0.051970806,0.00043304378],"about_ca_topic_score_codex":0.009829224,"about_ca_topic_score_gemma":0.009153218,"teacher_disagreement_score":0.5304463,"about_ca_system_score_codex":0.015191987,"about_ca_system_score_gemma":0.025159396,"threshold_uncertainty_score":0.65413475},"labels":[],"label_agreement":null},{"id":"W4408972758","doi":"10.1007/s41669-025-00567-1","title":"Cost-Effectiveness Analysis of Daridorexant for the Pharmacological Treatment of Chronic Insomnia Disorder in Adults","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Sleep and related disorders","field":"Psychology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université Laval","funders":"Idorsia Pharmaceuticals","keywords":"Insomnia; Chronic insomnia; Medicine; Physical therapy; Psychiatry; Sleep disorder","score_opus":0.05065804717556651,"score_gpt":0.4323878008586311,"score_spread":0.3817297536830646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408972758","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.81642914,0.07790287,0.046707407,0.008582834,0.00048252693,0.003433756,0.0102337,0.00030220582,0.03592555],"genre_scores_gemma":[0.98847735,0.00442968,0.004431615,0.0003221361,0.000049007846,0.00038796858,0.0008768717,0.000014054204,0.001011255],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.99735594,0.002066641,0.00009063568,0.0001219691,0.00022688619,0.0001380822],"domain_scores_gemma":[0.9952917,0.0039151665,0.00033181033,0.00006844781,0.00024329072,0.00014951914],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0052298238,0.0010901791,0.001612804,0.0010976875,0.00021181628,0.0015445565,0.0009311461,0.0011151275,0.004435477],"category_scores_gemma":[0.012002215,0.0005682958,0.0038998278,0.000918818,0.0002938518,0.0011373711,0.00068753294,0.0013293712,0.00019474534],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01010132,0.00048321535,0.008959205,0.0032161083,0.0052897357,0.00032394024,0.000084150764,0.90417534,0.00061717484,0.009332479,0.002577387,0.05483998],"study_design_scores_gemma":[0.005640362,0.006641697,0.01890015,0.0023728327,0.012846241,0.0006601859,0.00027855087,0.9332156,0.0008847889,0.0101329535,0.008289128,0.00013751],"about_ca_topic_score_codex":0.015763137,"about_ca_topic_score_gemma":0.009799711,"teacher_disagreement_score":0.015763137,"about_ca_system_score_codex":0.006588629,"about_ca_system_score_gemma":0.0037741598,"threshold_uncertainty_score":0.047804058},"labels":[],"label_agreement":null},{"id":"W4409906719","doi":"10.1007/s41669-025-00579-x","title":"Assessing the Value for Money of Enzyme Replacement Therapy in Gaucher Disease Types 1 and 3b: Can Expanded Coverage Be Justified?","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Lysosomal Storage Disorders Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute for Work & Health","funders":"Faculty of Medicine Siriraj Hospital, Mahidol University; Thailand Science Research and Innovation; King Chulalongkorn Memorial Hospital","keywords":"Enzyme replacement therapy; Value (mathematics); Glucocerebrosidase; Disease; Value for money; Economics; Medicine; Psychology; Internal medicine; Public economics; Statistics; Mathematics","score_opus":0.07914948478163432,"score_gpt":0.44021923930942997,"score_spread":0.36106975452779566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409906719","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8012871,0.042926364,0.04771194,0.05634806,0.0004531658,0.0009365256,0.0033133235,0.000089522255,0.046934098],"genre_scores_gemma":[0.99136436,0.0035881607,0.0039106333,0.00039301778,0.00007001963,0.00008301045,0.0002031871,0.0000073812403,0.0003802591],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.98964256,0.008653256,0.00028804922,0.00026052725,0.0007722665,0.00038327943],"domain_scores_gemma":[0.95042706,0.043290574,0.0034560498,0.0003711322,0.0017258846,0.0007291983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.011966549,0.00074637885,0.00094430044,0.0019463819,0.00031848834,0.0031540124,0.00088365446,0.0014342716,0.005176407],"category_scores_gemma":[0.050753497,0.00031201256,0.00093894807,0.0021303166,0.0012802406,0.0033216653,0.0013242338,0.0017460445,0.00017254327],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0050802724,0.0005165006,0.14433797,0.0044852747,0.0018688976,0.0013485126,0.0011106959,0.38898906,0.00076832203,0.09536325,0.010205222,0.34592608],"study_design_scores_gemma":[0.0008155216,0.0027537951,0.07510707,0.0068220976,0.0022349714,0.0014878751,0.005218563,0.6538758,0.002499793,0.21934679,0.02951976,0.00031798368],"about_ca_topic_score_codex":0.008358533,"about_ca_topic_score_gemma":0.0061521227,"teacher_disagreement_score":0.011966549,"about_ca_system_score_codex":0.005081797,"about_ca_system_score_gemma":0.0063954797,"threshold_uncertainty_score":0.06328589},"labels":[],"label_agreement":null},{"id":"W4415481382","doi":"10.1007/s41669-025-00606-x","title":"The Consistency and Transferability of Economic Evaluations of Disease-Modifying Treatments for Multiple Sclerosis: Analysis of Cost-Effectiveness Assessments from Australia, England, Canada and Scotland","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Health Systems, Economic Evaluations, Quality of Life","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Newcastle University","keywords":"Consistency (knowledge bases); Transferability; Nice; Economic evaluation; Value (mathematics); Key (lock)","score_opus":0.4556949474363551,"score_gpt":0.5296241747478914,"score_spread":0.07392922731153628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415481382","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97635084,0.0073892213,0.004324462,0.0009142008,0.000040829887,0.00049595686,0.002708135,0.00002923072,0.00774701],"genre_scores_gemma":[0.9956405,0.0008641698,0.0017604207,0.00007096477,0.0000117729505,0.00008656099,0.001381106,0.000010477991,0.00017409459],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.83774364,0.08539481,0.019142218,0.005355104,0.049305853,0.0030583972],"domain_scores_gemma":[0.61581206,0.27037862,0.048836086,0.0151038645,0.048442204,0.0014272155],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.11124965,0.00069082814,0.0020148626,0.0100725265,0.00080429245,0.004918567,0.001963794,0.00061542256,0.00097374734],"category_scores_gemma":[0.44956174,0.0004677173,0.0024375604,0.014877285,0.0017334875,0.0022256095,0.003949764,0.0013954651,0.000091747104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025776012,0.00013653467,0.83276576,0.0021491218,0.011837657,0.0006814066,0.0046992153,0.01605862,0.00035968525,0.0039638723,0.0012029113,0.12356759],"study_design_scores_gemma":[0.00020676003,0.00030939974,0.98175114,0.00090237183,0.0018072936,0.00030504682,0.0016781475,0.008864658,0.00041724436,0.0010478768,0.002603477,0.00010661013],"about_ca_topic_score_codex":0.28158557,"about_ca_topic_score_gemma":0.19669318,"teacher_disagreement_score":0.7184144,"about_ca_system_score_codex":0.0128981,"about_ca_system_score_gemma":0.010733638,"threshold_uncertainty_score":0.58835137},"labels":[],"label_agreement":null},{"id":"W4416015139","doi":"10.1007/s41669-025-00610-1","title":"Venetoclax in Combination with Obinutuzumab in Previously Untreated Fit Patients with Chronic Lymphocytic Leukemia: A Canadian Cost-Utility Analysis","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Manitoba; Research Institute in Oncology and Hematology; ABB (Canada); CancerCare Manitoba; University of Calgary","funders":"","keywords":"Venetoclax; Obinutuzumab; Ven; Chronic lymphocytic leukemia; Ibrutinib; Bendamustine; IGHV@; Cancer","score_opus":0.019483530240405847,"score_gpt":0.3295830902794832,"score_spread":0.31009956003907735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416015139","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.8980718,0.053756498,0.0055402196,0.0037158118,0.00012741867,0.0014940765,0.019969976,0.00012618207,0.01719803],"genre_scores_gemma":[0.98571026,0.00585243,0.0029100738,0.00030864618,0.000027860984,0.00015730526,0.00392637,0.000021220314,0.0010859214],"study_design_codex":"simulation_or_modeling","study_design_gemma":"observational","domain_scores_codex":[0.9982768,0.00093141105,0.00006898584,0.0001301735,0.00035268645,0.00023988188],"domain_scores_gemma":[0.99552083,0.0028457332,0.00041395915,0.00014481784,0.00070708507,0.00036756942],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004795838,0.0011564443,0.001757408,0.0020034048,0.00064900785,0.0016098889,0.0014999592,0.000771104,0.0035513076],"category_scores_gemma":[0.011364452,0.0005145935,0.0050282064,0.0032646754,0.0005077619,0.0005135706,0.00069522084,0.001334624,0.00012408756],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0322,0.0012800484,0.1225531,0.0060135606,0.026299484,0.0010067563,0.00031738842,0.6742672,0.0010441097,0.009349244,0.017289203,0.10837991],"study_design_scores_gemma":[0.015259049,0.004530946,0.1497959,0.0023655382,0.039272837,0.0009382462,0.0007063785,0.7557669,0.0007855917,0.0066360016,0.023542924,0.00039964242],"about_ca_topic_score_codex":0.8743008,"about_ca_topic_score_gemma":0.85481954,"teacher_disagreement_score":0.12569922,"about_ca_system_score_codex":0.041202873,"about_ca_system_score_gemma":0.022185614,"threshold_uncertainty_score":0.29894918},"labels":[],"label_agreement":null},{"id":"W4416197305","doi":"10.1007/s41669-025-00613-y","title":"Cost of Chronic Heart Failure Among Adult Europeans—A Systematic Literature Review","year":2025,"lang":"en","type":"article","venue":"PharmacoEconomics - Open","topic":"Heart Failure Treatment and Management","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Systematic review; Heart failure; Protocol (science); MEDLINE; Medical literature","score_opus":0.021714652397324567,"score_gpt":0.3485529109715103,"score_spread":0.32683825857418575,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416197305","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0021836902,0.9961138,0.00014233496,0.0002505636,0.000082852006,0.0002212866,0.00075750053,0.0000063490643,0.00024147607],"genre_scores_gemma":[0.038257327,0.9592811,0.00076337357,0.00045299696,0.000104878905,0.0005419705,0.00051247317,0.0000066835214,0.000079241756],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9902683,0.0036680566,0.0035273153,0.0006988705,0.0015957863,0.00024176399],"domain_scores_gemma":[0.9766308,0.016171878,0.004813142,0.00027581584,0.001921745,0.00018649643],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01114021,0.0016828304,0.0093804505,0.013518037,0.0004933874,0.002859528,0.0015552309,0.0015819586,0.0037871879],"category_scores_gemma":[0.04288948,0.00093941164,0.011600538,0.011764269,0.00064016046,0.002118136,0.001439546,0.0010488678,0.00016333585],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004020015,0.000022596889,0.0024425387,0.9154422,0.040283486,0.000117101335,0.00011197398,0.0003088695,0.000055790184,0.00031512318,0.0015614241,0.038936846],"study_design_scores_gemma":[0.000601499,0.00030924313,0.013306079,0.7900323,0.18194433,0.0006584258,0.0002887056,0.000292229,0.00014607584,0.0005518955,0.011805678,0.00006354738],"about_ca_topic_score_codex":0.008795315,"about_ca_topic_score_gemma":0.016560435,"teacher_disagreement_score":0.013518037,"about_ca_system_score_codex":0.004602229,"about_ca_system_score_gemma":0.0073378757,"threshold_uncertainty_score":0.058915794},"labels":[],"label_agreement":null}]}